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ABSTRACT  
 
Charles University in Prague 
Faculty of Pharmacy in Hradec Králové 
Department of Biochemical Sciences 
 
Candidate: Tereza Hartmanová 
Supervisor: Dr. Claudia Staab, Dr. Hans-Jörg Martin, Prof. Ing. Vladimír Wsól, Ph.D. 
Title of the diploma thesis: Studies on carbonyl reductases 1 and 3 variants with 
emphasis on S-nitrosoglutathione as substrate and inactivator 
 
Human CBR1 and CBR3 (carbonyl reductases 1 and 3) are monomeric,  
NADPH-dependent enzymes belonging to the short chain dehydrogenase/reductase 
superfamily. Although they are highly similar at the amino acid level (72 % identity) the 
enzymes exhibit considerable differences in substrate specificity. The CBR1 substrate 
spectrum is well described, including a variety of compounds e.g. the endogenous indol 
isatin, S-nitrosoglutathione (GSNO), prostaglandins, quinones, and many carbonyl 
group bearing xenobiotics. In contrast, CBR3 shows a distinct and much narrower range 
of substrates and its role is still not fully clarified. Nevertheless, the dissimilar substrate 
spectra strongly indicate that CBR1 and CBR3 play different metabolic roles.  
In the present study, the catalytic properties of CBR1 towards the latest CBR1 
substrate described, GSNO, were investigated. CBR3 was assessed for potential  
GSNO-reducing activity, but no in vitro activity was observed. Thus, to assess the 
residues and mechanism responsible for the CBR1 properties, a certain number of 
amino acid residues of CBR3 were replaced to correspond to CBR1. The variants were 
created using splicing by overlap extension, cloned into the pET-28b(+) vector, 
overexpressed in E. coli and purified via Ni-affinity chromatography. We found out that 
GSNO was an acceptable substrate for several CBR3 variants, interestingly all of them 
comprising the change in sequence at positions 236-244, that also influenced catalytic 
properties with isatin and 9,10-phenantrenequinone. In CBR1, together with all variants 
with catalytic activity determined, inactivation starting at a GSNO concentration of 
about 100 µM was detected. Further investigations, including reactivation of CBR1 by 
treatment with dithiothreitol suggested cysteine S-glutathionylation as the underlying 
mechanism. 
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ABSTRAKT 
 
Universita Karlova v Praze 
Farmaceutická fakulta v Hradci Králové 
Katedra biochemických věd 
 
Kandidát: Tereza Hartmanová 
Školitel: Dr. Claudia Staab, Dr. Hans-Jörg Martin, Prof. Ing. Vladimír Wsól, Ph.D. 
Název diplomové práce: Studium mutací karbonylreduktasy 1 a 3 s důrazem na  
S-nitrosoglutathion jako substrát a inaktivátor 
 
Lidské CBR1  a CBR3 (karbonylreduktasa 1 a 3) jsou monomerní, na NADPH 
závislé enzymy patřící do nadrodiny dehydrogenas/reduktas s krátkým řetězcem. 
Přestože na aminokyselinové úrovni si jsou oba enzymy velmi podobné (72 % shoda), 
v substrátové specifitě vykazují značné rozdíly. Substráty CBR1 jsou velmi dobře 
popsány. Zahrnují řadu látek jako endogenní indol isatin, S-nitrosoglutathion (GSNO), 
prostaglandiny, chinony a mnoho xenobiotik, které obsahují karbonylovou skupinu. Na 
rozdíl od CBR1 je výčet substrátů CBR3 mnohem menší a různorodý a role CBR3 stále 
není plně objasněna. Přesto tyto odlišnosti v substrátové specifitě naznačují rozdílné 
metabolické role.  
V této práci byly studovány katalytické vlastnosti CBR1 a jejího posledního 
popsaného substrátu, GSNO. Možné domněnky, že CBR3 by mohla také redukovat 
GSNO nebyly in vitro potvrzeny. Proto, k odhadnutí aminokyselin a mechanismů 
zodpovědných za vlastnosti CBR1, byly určité aminokyseliny v sekvenci CBR3 
změněny tak, aby odpovídaly sekvenci CBR1. Mutanty byly vytvořeny pomocí splice 
overlap extension metody, naklonovány do vektoru pET28, namnoženy v E. coli a 
purifikovány pomocí Ni-afinitní chromatografie. Bylo zjištěno, že GSNO je přijatelným 
substrátem pro několik CBR3 mutantů. Zajímavé bylo, že všechny z nich obsahovaly 
mutace na pozicích 236-244, které také ovlivňují katalytické vlastnosti vůči isatinu a 
9,10-phenantrochinonu. CBR1 společně se všemi mutanty vykazujícími aktivitu vůči 
GSNO byly GSNO inaktivovány. Inaktivace začínala zhruba při 100 µM koncentraci 
GSNO. Následující výzkum zahrnující reaktivaci CBR1 pomocí inkubace s 
dithiothreitolem nasvědčuje, že inaktivačním mechanismem je S-glutathionylace 
cysteinů. 
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1 INTRODUCTION 
 
Maintaining the body´s balance in chemical composition is a constant, dynamic 
process, which is regulated continuously. The majority of catalytic reactions that assure 
this equilibrium are mediated by enzymes. Almost all processes in a biological cell 
require enzymes to occur. Enzymes are largely specific for their substrates, i.e. every 
enzyme only speeds up one reaction or a small set of reactions from many options. 
Hence, the set of enzymes expressed in a particular cell determines the occurring 
metabolic pathways. 
 Nowadays, the human body has to deal with a number of foreign substances which 
are not natural, i.e. are not part of the normal constitution of the human body and often 
have harmful effects. These compounds, the so-termed xenobiotics, are found in food, 
air and medication. The most common xenobiotics are drugs or environmental 
pollutants. The process that describes how the human body excretes these substances is 
called biotransformation and consists of a set of metabolic pathways which collectively 
alter the chemical structure of xenobiotics. These pathways, which are considered to be 
of ancient origin, often act to protect from damaging effects of xenobiotics and can be 
found in all major groups of organisms. 
As a tight control of enzyme activity is necessary for keeping stable conditions 
inside the body, every single change of an enzyme can cause a genetic disease. The 
major role of enzymes is demonstrated by the fact that just one single damaged enzyme 
out of the thousands can cause a lethal illness. In addition, increased expression levels 
of certain enzymes can contribute to disease and then, enzyme inhibition can be used for 
treatment e.g. in the case of high blood pressure or diabetes. Research is also being 
conducted on malfunctioning enzymes linked to blood disorders e.g. anaemia. 
Furthermore, geneticists have discovered that in some hereditary diseases total absence 
of some enzyme is the cause of the defect. Some of these enzyme-deficiency disorders 
can be treated by the supply of the enzyme. In summary, the biochemical 
characterization of enzymes is of great interest as enzymes play essential roles in 
normal human physiology as well as contribute to pathophysiology if they are damaged 
or their levels altered.  
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2 THEORETICAL PART 
 
2.1 Redox reactions in metabolism  
 
Redox (reduction-oxidation) reactions play a major role in all 
biotransformational phases of xenobiotic metabolism. The way a compound passes 
through the body is described by metabolic processes called absorption, distribution, 
metabolism and excretion. All these reactions are divided into three main phases of 
metabolism. Nonsynthetic phase I reactions may include oxidation, reduction or 
hydrolysis. Oxidation means the enzymatic addition of oxygen or disposal of hydrogen 
from a lipophilic compound, making it more polar and thus more water-soluble. Many 
phase I enzymes are located in the ER membrane. The predominant enzymes of ER 
oxidative metabolism are the monooxygenases. There are two major types of 
microsomal monooxygenases: the cytochrome P450 (cyt P450) system and the flavin-
containing monooxygenases. The cytochrome P450 system is involved in the oxidative 
metabolism of many endogenous substances, as well as the detoxification of a wide 
variety of xenobiotics. Flavin-containing monooxygenases catalyse the oxidation of 
substances (primarily xenobiotics) bearing functional groups containing nitrogen, 
sulphur or phosphorus.  
Reductive phase I reactions have also been described and may be of great 
pharmacological importance. For the most part, reductive routes in phase I are 
accomplished by members of the aldo-keto reductases (AKR) and short-chain 
dehydrogenases/reductases (SDR) superfamilies and the quinone reductases (QR), the 
subgroup of the MDR (medium-chain dehydrogenase/reductase) superfamily. These 
families are known to constitute important phase I enzymes (Oppermann and Maser 
2000). 
In phase II, the polar functional groups of phase I derivatives are conjugated 
with carboxyl (-COOH), hydroxyl (-OH), amino (NH2), and sulfhydryl (-SH) groups 
found in sulfonates, glutathione, glucuronic acid or amino acids. The enzymes that 
initiate this activation are called transferases. The conjugated products are often inactive 
in comparison to the corresponding phase I metabolites. Additionally, the phase II 
product can be further modified and metabolised in phase III for transport out of the 
cell.  
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A non-physiological condition related to redox state is oxidative stress. 
Normally, a reducing environment is present in the cells. However, when cells are not 
able to metabolically cope with the production of peroxides, free radicals and other 
reactive oxygen species (ROS), unnatural oxidative redox conditions arise. Many 
enzyme groups are involved in the metabolism of ROS. Among the best studied 
implicated enzymes are superoxide dismutase, catalase and glutathione peroxidase and 
researchers are intensively studying other enzyme families involved. 
  
2.2 Carbonyl reduction 
 
Although the endogenous carbonyl metabolism is well described, the roles of 
carbonyl-reducing enzymes in xenobiotic metabolism are still not well elucidated 
(Rosemond and Walsh 2004). Unarguably, carbonyl reduction plays a major role in the 
phase I metabolism of carbonyl substances. This role consists in an inactivation or 
detoxication of the reactive aldehyde or ketone moiety through reduction to a hydroxyl 
group (Hoffmann and Maser 2007). The reaction products are less lipophilic than the 
parent compounds and therefore easier to conjugate and excrete (Testa and Kramer 
2007). 
The chemical carbonyl function (aldehyde or ketone group) frequently occurs in 
endogenous compounds such as hormones, mediators, cofactors, neurotransmitter 
precursors and lipid aldehydes derived from oxidative stress and their metabolites. 
Reactive, oxidative stress-related, carbonyl compounds (RCCs) are formed during lipid 
peroxidation and sugar glycoxidation. RCCs are the cause of the carbonyl stress, which 
results in the formation of adducts and protein cross-links leading to malfunctioning 
protein function and damages in all tissues (Negre-Salvayre, Coatrieux et al. 2008). The 
RCCs include substances such as acrolein, 4-hydroxynonenal and malondialdehyde. 
Furthermore, the carbonyl group is widely spread in xenobiotics such as alimentary 
products, medications, or environmental pollutants. In endogenous substances the 
carbonyl group is often a determining factor for the biological activity, e.g. the 3-keto 
group in steroid hormones (Oppermann 2007).  
Carbonyl reducing enzymes (CRs) are found both in mammalian and 
non-mammalian organisms. Non-mammals using CRs are plants, bacteria, yeast, fish 
and insects.  Among mammals with determined CRs metabolic activity following 
species were identified: rabbit, hamster, mouse, monkey, chicken, pig, dog and cattle. 
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Human carbonyl-reducing enzymes occur in many different kinds of tissue, such as 
liver, lung, heart, kidney, brain, ovary and adrenal gland. Carbonyl reduction is 
performed by enzymes belonging to two main superfamilies i.e. the short-chain 
dehydrogenases/reductases family (SDR) and the aldo-keto reductases (AKRs). 
Enzymes from both superfamilies can catalyse the reduction of xenobiotic carbonyl 
compounds and endogenous steroids.  
 
2.3 Carbonyl reducing enzymes 
 
2.3.1 The aldo-keto reductase superfamily 
 
The aldo-keto reductase (AKR) superfamily comprises at present 160 known 
enzymes of monomeric, mostly NADPH-dependent, oxidoreductases with a length of 
about 320 amino acids, that bind their cofactor without a Rossmann-fold motif (Jez, 
Bennett et al. 1997). AKRs are involved in biosynthesis, intermediary metabolism, and 
detoxication. Steroids, glucose, glycosylation end-products, lipid peroxidation products 
and environmental pollutants belong to the AKR substrates.  
All AKRs possess a double domain protein with a βαβ fold characteristic of 
nucleotide binding proteins (Schade, Early et al. 1990). The AKRs contain a parallel 
β8/α8-barrel motif. The substrate-binding site is located in a large, deep elliptical pocket 
at the C-terminal end of the β barrel with a bound NADPH in an extended conformation 
(Wilson, Bohren et al. 1992).  The lipophilic nature of the pocket prefers aromatic and 
apolar substrates over polar ones. The active site of the AKR members contains a highly 
conserved tetrade of the amino acids Tyr, His, Asp and Lys. Based on sequence 
comparisons, the AKR superfamily has been subdivided into 15 families, namely AKR 
1-15 (Barski, Tipparaju et al. 2008). Further information about the AKR superfamily 
can be found at Dr. T. Penning‟s web site http://www.med.upenn.edu/akr. 
 
2.3.2 The short-chain dehydrogenase/reductase superfamily 
 
The enzymes belonging to the short-chain dehydrogenase/reductase (SDR) 
superfamily form another large carbonyl reducing superfamily with no structural 
similarities to AKRs. SDRs represent one of the oldest protein superfamilies and are 
widespread in both procaryotic and eucaryotic organisms. At present, at least 70 
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characterised, highly different, human enzymes of this family are known (Bray, 
Marsden et al. 2009). To the main substrates metabolised by SDRs belong 
prostaglandins, steroids, sugars and aromatic hydrocarbons. The superfamily is made up 
of enzymes averaging 250-350 amino acids in length (Hoffmann and Maser 2007). 
Most of the SDRs are known to be NAD- or NADP- dependent oxidoreductases. The 
sequence identity between SDR family members ranges typically between 15-30 % in 
pairwise comparisons (Kallberg, Oppermann et al. 2002); nevertheless, they share 
common structural properties.  
 First, the SDR superfamily was divided into two major families, "classical" and 
"extended". The "classical" SDRs have about 250 amino acid residues in length, while 
the "extended" family members have an additional 100-residue domain in the C 
terminal region (Jörnvall, Persson et al. 1995). The classical SDRs have a relatively 
small α-helical substrate binding site. The extended SDRs have a larger substrate 
binding site, including a two-stranded parallel β-sheet and an α-helix bundle containing 
three helices. Beyond that, the two families have different glycine-motifs in the cofactor 
binding part. 
  Later, the SDR superfamily was clustered into six families, namely the 
“intermediate” , “divergent” , “complex” (Persson, Kallberg et al. 2003) and “atypical“ 
families, in addition to the established “classical” and “extended” families (Figure 1).  
 
 
 
 
Figure 1: Classification of SDRs  
 
The Rossmann fold, a common dinucleotide binding motif composed of βαβ 
units is the most important unifying feature of SDRs (Duax, Ghosh et al. 2000) 
additionally to its presence in long-chain dehydrogenases/reductases and medium-chain 
dehydrogenases/reductases (Kavanagh, Jörnvall et al. 2008). In SDRs, the catalytic site 
typically includes a highly conserved amino acid triad composed of the amino acids Ser, 
Tyr and Lys, even though variations on this motif also exist. Generally, it is the most 
common nucleotide cofactor binding domain. Furthermore, SDR proteins have a 
SDRs
classical extended intermediate divergent complex atypical
13 
 
structurally conserved N-terminal region with a glycine-rich pattern (TGxxxGxG), 
which contributes to NAD(H) or NADP(H) cofactor binding (Jörnvall, Persson et al. 
1995; Tanaka, Nonaka et al. 1996) and a structurally variable C-terminal region, 
consisting of several α-helices, that binds the substrate. During the reaction, a fixed 
binding order is kept: the cofactor binds in the first place, subsequently followed by the 
substrate (Grimm, Maser et al. 2000). This fixed binding order is called sequential 
ordered bi-bi mechanism or bi-bi reaction. 
 
2.3.3 New nomenclature of SDRs 
 
Because SDRs form one of the largest enzyme superfamilies with more than  
46.000 members found in the Uniprot and Refseq sequence databases and the number of 
newly described SDRs is still increasing, the establishment of a systematic 
nomenclature was needed. Therefore, a new nomenclature system has been established 
by Persson, Kallberg et al. 2009. In the new nomenclature scheme, each SDR family 
has been given a number. At present, there are 48 human SDR families detected. The 
numbering begins with the SDR families found in human with lowest numbers, 
followed by families from mammals or other eukaryotic members. Next, SDR families 
with members present both in bacteria and archaea and last, SDR families present just in 
bacteria were numbered. All SDR families are listed on the SDR web page 
http://www.sdr-enzymes.org.  
The family number is followed by  a letter signifying the SDR type, namely 
“classical” (C), “extended” (E), “intermediate” (I), “divergent” (D), “complex” (X) and 
“atypical“ (A) SDRs. All these types differ in properties of the specific sequence 
patterns at the coenzyme binding and active site (for more information about the 
specific features of different types of SDRs see reference Kavanagh, Jörnvall et al. 
2008.) The last distinguishing letter in the nomenclature scheme is the number at the 
end giving to each member of SDR family a specific individual denotation (see Figure 
2). This system makes the nomenclature hierarchical, but still clearly informative. Using 
the new nomenclature CBR1 is reported as SDR21C1, CBR3 as SDR21C2 (Persson, 
Kallberg et al. 2009). Nevertheless, in this thesis we stick to the “old” nomenclature as 
the “new” nomenclature is still not fully implemented.   
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Figure 2: New nomenclature system of SDRs (CBR1 in this case)  
 
2.3.4 Carbonyl reductases of the SDR superfamily 
 
Several members of the SDR superfamily have been shown to reduce 
endogenous and xenobiotic carbonyl compounds in vitro. Among human CBRs, the best 
studied member is carbonyl reductase 1 (CBR1) (Oppermann 2007), followed by the 
much less known carbonyl reductase 3 (CBR3). Carbonyl reductases belong to the 
"classical" SDR family.  
A special case is the enzyme called carbonyl reductase 4 (CBR4) with less than 
30 % similarity and different substrate specifity in comparison to the other two CBRs. 
Further, CBR4 differs in terms of subcellular localization and subunit structure (Endo, 
Matsunaga et al. 2008). Here, the old nomenclature is clearly misleading and according 
to the new nomenclature CBR4 is numbered as SDR45C1 (Persson, Kallberg et al. 
2009). This classification is strongly different from SDR21C1 (CBR1) and SDR21C2 
(CBR3) and points out that they are not related apart from the SDR features.  
 
2.3.5 Carbonyl reductase 1 (CBR1)  
 
CBR1 was first isolated from human brain in 1973 by Ris and von Wartburg 
(Ris and von Wartburg 1973). CBR1 is a low molecular weight, monomeric, cytosolic, 
NADPH-dependent enzyme of the SDR superfamily with broad substrate specificity for 
many endogenous and xenobiotic carbonyl compounds. It is mapped to chromosome 21 
at 21q22.12 and composed of 277 amino acids. The best known substrates include 
endogenous prostaglandins, steroids and other aliphatic aldehydes and ketones (Forrest 
and Gonzalez 2000). Regarding xenobiotics, CBR1 reduces p-quinones, anthracyclines, 
ketoaldehydes, aromatic aldehydes and NNK (4-(methylnitrosamino)-1-(3-pyridyl)-1-
butanone), the carcinogenic nitrosamine of tobacco smoke (Atalla and Maser 2001; 
Finckh, Atalla et al. 2001).  
1 C 21 SDR 
RRr 
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Immunohistochemical staining showed presence of CBR1 in all organs assessed 
(Wirth and Wermuth 1985; Wirth and Wermuth 1992), but the various level of staining 
indicated a heterogeneous distribution in the body. Strong staining was found in liver, 
epidermis, stomach, small intestine, kidney, CNS, pituitary gland, smooth muscle fibres, 
blood vessels and cardiac muscle. Poor staining was located in connective tissue and 
CNS. Weak or no staining was observed in cerebellum, oral cavity, oesophagus, 
seminal vesicle, epididymis, vas deferens, prostate gland, glomerular capsule, thyroid 
gland, pancreas, ovary and skeletal muscle fibres (Forrest and Gonzalez 2000).  
In general, CBR1 catalyses the following reaction: 
 
 
 
Figure 3: General reaction catalysed by CBR1 
 
As mentioned above, CBR1 metabolises a broad spectrum of substrates. The first 
reports about CBR1 indicated that CBR1, also named 9-ketoreductase or 
15-hydroxyprostaglandin dehydrogenase, was involved in prostaglandin and steroid 
metabolism. But later Wermuth found out that quinones based on the polycyclic 
aromatic structure, were much better substrates (Wermuth, Platts et al. 1986), with 
ubiquinone-1, menadione, and 9,10-phenanthrenequinone representing the best ones 
(Forrest and Gonzalez 2000). In prostaglandin metabolism, CBR1 inactivates PGE2 by 
conversion to PGF2α. The glutathione (GSH) adduct of PGA1 is also reduced by 
CBR1, in contrast to free PGA1, which is not metabolised at all (Wermuth 1981). 
However, the velocity of PGE1 and PGE2 reduction was approximate 50 times lower 
than the velocity of menadione reduction. Nevertheless, according to Kelner, CBR1 
may play an in vivo role in prostaglandin metabolism (Kelner, Estes et al. 1997). 
Ketoaldehydes (e.g. phenylglyoxal), aromatic aldehydes containing an 
electrophilic substituent (e.g. 4-nitrobenzaldehyde), and the biogenic aldehydes, 
indoleacetaldehyde and 4-hydroxyphenylacetaldehyde, were also readily metabolised  
although fairly high concentrations were required (Wermuth 1981). The lowest 
Michaelis constants and the highest maximal velocities were measured for ubiquinone 
and menadione (Wermuth 1981) and menadione is often used as a model substrate. 
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Quinones are converted to semiquinone radicals in a one-electron reduction or to 
hydroquinones in a two-electron reduction. Hydroquinones can be further conjugated in 
phase II and excreted (Oppermann 2007). This mechanism is involved in detoxication 
of endogenous substances and xenobiotics. On the other hand CBR1 plays a role in 
toxication e.g. the conversion of the anthracycline-based chemotherapeutical drugs 
daunorubicin and doxorubicin, resulting in cardiotoxicity.   
 Further reductase activity, comparable to menadione values, was found with the 
endogenous indole substrate isatin (indole-2,3-dione) (Usami, Kitahara et al. 2001; El-
Hawari, Favia et al. 2009). Previously, no endogenous substrates had shown so high 
activity values and isatin has become the best known endogenous substrate for CBR1 
(Usami, Kitahara et al. 2001). Isatin is an endogenous oxidised indole with a wide 
spectrum of behavioural and metabolic effects. Isatin and its derivatives form the base 
of many natural substances. Its output is increased during stress. Antagonism of atrial 
natriuretic peptide function and a role in NO signalling are the best described functions 
of isatin (Medvedev, Buneeva et al. 2007).  
CBR1 plays a protective role in oxidative stress, tumour metastasis, 
neurodegeneration and apoptosis (Ismail, Al-Mulla et al. 2000; Botella, Ulschmid et al. 
2004). Although no clear evidence explains which substrate is responsible for those 
effects, a study showed, that, in vitro, CBR1 inactivates the lipid aldehyde 4-oxo-2-
nonenal (Carbone, Doorn et al. 2004), which is formed during oxidative stress. This 
supports the idea that CBR1 is involved in the oxidative stress response and elimination 
of reactive oxygen species (Pilka, Niesen et al. 2009). 
 
2.3.6 CBR1 and S-nitrosoglutathione reduction 
 
The fact that the glutathione adduct of PGA1 is reduced by CBR1 (free PGA1 is 
not) suggested the presence of a GSH-binding pocket close to the catalytic site.  
Bateman, Rauh et al. (2008) identified the GSH-binding site in the cleft of the enzyme 
site with the GSH-Cys oriented towards the nicotinamide moiety of the cofactor. 
Interactions between GSH and CBR1 are mediated along the entire GSH tripeptide 
structure. CBR1 contains five cysteine residues (positions 26, 122, 150, 226 and 227). 
To identify the reactive cysteine residue and investigate its possible role in GSH 
binding, each cysteine residue of human CBR1 was substituted with alanine by 
site-directed mutagenesis. Only the mutant Cys227Ala influenced the activity and this 
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position was suggested as the reactive residue involved in glutathione binding. The 
Cys227Ala mutant revealed 10 to 15-fold reduced kcat values in comparison to CBR1 
wild type and the other four mutants, although addition of chloride rescued the activity 
of the enzyme (Tinguely and Wermuth 1999). The Cys227Ser mutation caused a similar 
decrease in activity as in the case of the Cys227Ala mutant, except that NaCl did not 
rescue the activity (Tinguely and Wermuth 1999). This was explained by the fact that 
the position 227 in the Cys227Ala mutant is occupied by a chloride ion (Bateman, Rauh 
et al. 2008).  
S-nitrosoglutathione (GSNO), a nitrogen-containing GSH adduct, has recently 
been identified as an endogenous substrate with kinetic parameters comparable to the 
isatin and menadione values. Human CBR1 appears specific for this S-nitrosothiol, 
because the reduction of S-nitrosocysteine is not catalysed by CBR1. Before that report, 
CBR1 had only been known to reduce carbonyl groups to alcohol. The reduction of 
GSNO represents a different mechanism of reduction, where an NO bond is reduced. 
Furthermore, it was demonstrated that CBR1-dependent GSNO reduction occurs in 
A549 lung adenocarcinoma cell lysates. These findings indicated that CBR1 may play a 
role in the regulation of tissue levels of GSNO (Bateman, Rauh et al. 2008). 
 
2.3.7 Carbonyl reductase 3 (CBR3) 
 
CBR3 was discovered by Wanatabe, Sugawara et al. (1998) during the mapping 
of chromosome 21. The CBR3 gene location is 62 kb downstream from the original 
CBR1 gene on human chromosome 21q22.2. It is composed of 277 amino acids. The 
physiological role of CBR3 is still not fully clarified. CBR3 has been classified as a 
monomeric, cytosolic, NADPH-dependent oxidoreductase (Hoffmann and Maser 2007). 
The highest tissue distribution was detected in ovary, pancreas and intestine. 
Sex-specific expression was observed. Compared to ovary, lower concentrations were 
determined in prostate and testis (Miura, Nishinaka et al. 2008).  
The CBR3 substrate spectrum is much narrower compared to CBR1. 1,2-
naphthoquinone belongs to the best substrates for CBR3 and, interestingly, an overall 
preference of CBR3 for o-quinones is apparent (Pilka, Niesen et al. 2009). Although 
menadione has originally been reported as a CBR3 substrate (Lakhman, Ghosh et al. 
2005), later studies revealed no CBR3 activity towards menadione (Miura, Nishinaka et 
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al. 2008; El-Hawari, Favia et al. 2009; Pilka, Niesen et al. 2009). To the non-quinone 
substrates of CBR3 belong oracin and isatin (Pilka, Niesen et al. 2009).   
 
2.3.8 CBR1 versus CBR3 
 
CBR1 and CBR3 show 72 % identity and 85 % similarity at the amino acid level 
(for sequence alignment see Figure 4). This level of identity is relatively high, compared 
to 15-30 % identity in other SDRs (Miura, Nishinaka et al. 2008). Both enzymes are 
composed of 277 amino acids and their genes are located close to each other on 
chromosome 21. In SDR classification, the CBRs belong to the “classical” SDR type 
with 140Ser-194Tyr-198Lys as a catalytic conserved triad (Jörnvall, Persson et al. 
1995) and Gly-x-x-x-Gly-x-Gly motif as a glycine rich part of the Rossmann fold 
(Kallberg, Oppermann et al. 2002), with glycines at positions 12, 16, and 18. The 
catalytic triad is critically important for the enzyme function and seems to fix the 
position of cofactor and βαβ-folding (Hoffmann and Maser 2007). 
CBR1 and CBR3 were explored under identical conditions with 111 different 
carbonyl substrates such as polyols, eicosanoids, steroids and xenobiotic carbonyl 
compounds, known as substrates for various types of carbonyl reductases (Matsunaga, 
Shintani et al. 2006; Pilka, Niesen et al. 2009). For CBR1, significant activity was found 
in 43 out of 111 substances, with quinones forming the largest fraction. In contrast, 
CBR3 reduced a very limited number of substrates with significantly decreased activity 
compared to CBR1. As mentioned above, the best substrate for CBR3 in this study was 
1,2-naphthoquinone and a preference of CBR3 for o-quinones was evident. Another 
difference in substrate specificity was given by no activity of CBR3 towards 
eicosanoids or aliphatic carbonyls (Pilka, Niesen et al. 2009). 
The 3D structure of both enzymes is similar. The main distinguishing feature is 
the conformation of the substrate binding loop. CBR1 shows a more closed and 
lipophilic active site, while the loop in CBR3 is more “open” and hydrophilic 
(El-Hawari, Favia et al. 2009; Pilka, Niesen et al. 2009). Despite high sequence 
similarities, the active site differs in shape and surface properties. Critical residues for 
substrate recognition were identified by Pilka, Niesen et al. 2009. Due to the thiomethyl 
group of Met142, a narrower substrate binding cleft was found in CBR1. In CBR3, this 
residue is replaced by Gln142. Three main critical positions for substrate recognition 
were suggested, namely position 230 (Trp in CBR1, Pro in CBR3), position 236 (Ala in 
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CBR1, Asp in CBR3) and position 142 (Met in CBR1, Gln in CBR3) (Pilka, Niesen et 
al. 2009). Moreover, there are only two amino acids in the CBR1 and CBR3 alignment 
which are encoded by triplets where all three bases differ completely.  Trp230 is one of 
those two (El-Hawari, Favia et al. 2009) and was considered to be one of the important 
residues for catalysis. In the amino acid sequences of CBR1 among humans, rats, 
Chinese hamsters, and mice, the 230 tryptophan residue is highly conserved while in the 
human CBR3 the rigid amino acid proline occupies that position instead (Miura, Itoh et 
al. 2009). But in conclusion, Miura et al. 2009 presented the substitution of Pro230 for 
Trp230 in hCBR3 as having no apparent impact on their enzymatic activities and 
suggested that limited catalytic effect of carbonyl reductase activity of CBR3 in 
comparison to CBR1 is a common feature among animal species. In contrast, data from 
other studies indicate critical roles for Trp230 and Pro230 in surface properties of CBR1 
and CBR3, respectively, in activity towards p-quinones (El-Hawari, Favia et al. 2009; 
Pilka, Niesen et al. 2009).  
Additionally, in a sequence alignment of CBR1 and CBR3, nine amino acids at 
the C-terminal low-identity region, close to the catalytic cleft at positions 236-244, 
reveal low sequence similarity. In a mutant of CBR3, where these positions 236-244 
were substituted with the corresponding CBR1 sequence, activity towards isatin was 
detected, although it was hardly comparable to the activity of CBR1 wild type. Other 
poorly conserved parts were found in the C-terminal region, near the catalytic Ser139. 
Together 10 mutants were generated and examined for isatin and 
9,10-phenantrenequinone activity (El-Hawari, Favia et al. 2009). Interestingly, the 
change in CBR3 corresponding to CBR1 sequence at positions 230 and 236-244 
resulted in significantly higher catalytic efficiency with isatin and 
9,10-phenantrenequinone in comparison to the CBR3 wild type and other constructs 
without these mutations (El-Hawari, Favia et al. 2009).  
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Figure 4: Geneious alignment of CBR1 and CBR3  
 
 
2.4 NO metabolism focused on the role of GSNO 
 
2.4.1 Nitric oxide (NO) 
 
NO plays an important role in the nervous, immune and cardiovascular systems 
as a regulator and mediator of multiple processes. Besides mediating normal functions, 
NO has been implicated in pathophysiological states as hypertension, stroke, and 
neurodegenerative diseases. Nitric oxide is a short-lived, highly reactive and highly 
diffusible molecule (with a half-life of a few seconds) and synthesised by a group of 
NADPH-dependent enzymes called nitric oxide synthases (NOSs) from Arg and O2. 
Potentially, NO is also generated by the reduction of NOx species that are derived from 
exogenous and endogenous sources (Hess, Matsumoto et al. 2005).  
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Three isoforms of NOS are known, namely neuronal NOS (NOS1 or nNOS), 
endothelial NOS (NOS3 or eNOS) and inducible NOS (NOS2 or iNOS). The names are 
derived from the activity (iNOS) or tissue from where they have been first described 
(nNOS, eNOS). Irrespective of their names, all three isoforms can be found in a variety 
of tissues and cell types. nNOS and eNOS expression is constitutive, while iNOS 
requires a stimulus to induce the expression. The generated nitric oxide interacts with 
the haem group of guanylate cyclase and activates the formation of cGMP, a second 
messenger with a major role in a number of physiological processes including 
homeostasis, platelet aggregation, smooth muscle tone, and bone growth (Smolenski, 
Burkhardt et al. 1998; Francis and Corbin 1999; Sausbier, Schubert et al. 2000). 
 
2.4.2 Protein S-nitrosylation  
 
The effects of NO are mediated by a number of mechanisms, but S-nitrosylation, 
the reaction of NO with cysteine thiol groups in proteins, has emerged as one of the 
most important ones. S-nitrosylation is a physiologically important post-translational 
modification controlled by mechanisms that include both the removal and the addition 
of the NO group from a Cys residue (Hess, Matsumoto et al. 2005). These mechanisms 
affect a number of proteins implicated in a variety of cellular processes. Both 
endogenous and exogenous NO react with the sulphur atom from cysteine in proteins to 
form relatively long-lived, naturally occurring S-nitrosothiols (SNOs) (Stamler, Jaraki 
et al. 1992; Gaston, Singel et al. 2006). Although NOSs unarguably play a central role 
in S-nitrosylation (Jaffrey, Erdjument-Bromage et al. 2001), it becomes increasingly 
recognised that additional metalloproteins might promote cellular S-nitrosylation 
(Benhar, Forrester et al. 2008). 
S-nitrosylation can either increase or inhibit enzyme activity. The functional 
consequences of protein S-nitrosylation depend on the protein that is affected. 
S-nitrosylation has been shown to inhibit enzyme activity in cases such as the caspases, 
whereas in other proteins, such as matrix metalloproteinases, S-nitrosylation increases 
the activity of the enzymes.  
 Several studies have been published on the detection of potential S-nitrosylation 
sites. Perez-Mato, Castro et al. considered that the basic and acidic amino acids, 
enclosing the target cysteine, may affect and help to specify the position of the protein 
S-nitrosylation (Perez-Mato, Castro et al. 1999). The acid-base motif comprises 
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flanking acidic (Asp, Glu) and basic (Arg, His, Lys) residues (Stamler, Toone et al. 
1997). However, this influence is still controversial as recently another study has 
suggested that the acid-base motif is not responsible for the 
S-nitrosylation and emphasised the role of more distant charged residues (Marino and 
Gladyshev 2009). Another factor, which can influence the specific site of 
S-nitrosylation, is protein allostery caused by ions (Ca
2+
, Mg
2+
, H
+
) and O2-based 
modifications (Hess, Matsumoto et al. 2005).  
 
2.4.3 Protein denitrosylation 
 
The removal of an NO group, known as denitrosylation, is still not well 
characterised. SNOs are mostly labile compounds and non-enzymatic S-NO bond 
degradation may be caused by light, heat, reducing compounds, nucleophilic agents or 
metal ions resulting in radicals or ions (Benhar, Forrester et al. 2009). There are two 
main cellular physiological denitrosylating enzyme systems: the thioredoxin (Trx) 
system (Benhar, Forrester et al. 2008) and the S-nitrosoglutathione reductase (GSNOR) 
system (Liu, Hausladen et al. 2001). GSNOR is originally known as class III alcohol 
dehydrogenase or glutathione-dependent formaldehyde dehydrogenase.  According to 
the latest recommended nomenclature for the alcohol dehydrogenase family, GSNOR is 
termed alcohol dehydrogenase 3 (ADH3) (Duester, Farres et al. 1999; Staab, Hellgren et 
al. 2008). For more details about GSNOR see the GSNO chapter (2.4.4.).   
 The thioredoxin system comprises the Trx protein, TrxR (thioredoxin reductase) 
and NADPH. Thioredoxin is a protein with a redox-active disulphide in the conserved 
sequence -Cys-Gly-Pro-Cys- which is essential for its function.  Caspase 3 was used to 
determine the Trx system denitrosylating effect. Inhibition of the Trx system increased 
the amount of S-nitrosylated caspase 3 and subsequently, the Trx system was 
established as a denitrosylase for a broad spectrum of proteins (Benhar, Forrester et al. 
2008). Recent efforts to define the process of denitrosylation presumed a mixed-
disulphide product between  substrate and Trx or alternatively, the transfer of the NO 
group (Stoyanovsky, Tyurina et al. 2005; Benhar, Forrester et al. 2009). GSNO is also 
known as a substrate of the Trx reducing system (Nikitovic and Holmgren 1996). 
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2.4.4 S-nitrosoglutathione (GSNO) 
 
GSNO (see Figure 5) is the key low-mass SNO in biological systems (Stamler, 
Jaraki et al. 1992). It was first identified in human airways (Gaston, Reilly et al. 1993). 
In physiological synthesis, activated NO intermediates react with glutathione (GSH) to 
form GSNO (Hogg, Singh et al. 1996).  
 
2•NO + O2 → 2 •NO2 
•NO + •NO2 → N2O3 
GSH + N2O3 → GSNO + HNO2  
 
As a minor product GSNO is also formed in the oxidation of GSH by 
peroxynitrite (Moro, Darley-Usmar et al. 1994; van der Vliet, Hoen et al. 1998). 
Physiological levels of GSNO range between 1-10 µM (Gaston, Carver et al. 2003). 
GSNO is considered as an NO donor which releases NO under physiological conditions 
and serves as a reservoir and carrier for NO in vivo (Stamler, Jaraki et al. 1992; 
Lindermayr, Saalbach et al. 2005).  
SNO homeostasis in vivo is ensured by synthesis of NO and decomposition of 
GSNO,  the latter predominantly accomplished by GSNOR (Rusterucci, Espunya et al. 
2007). GSNOR is a specific NADH-dependent GSNO reductase (Liu, Hausladen et al. 
2001), although it is involved in formaldehyde metabolism as well (Benhar, Forrester et 
al. 2009). It has been revealed that the control of intracellular levels of both GSNO and 
S-nitrosylated proteins largely depends on GSNOR which helps to protect cells from 
nitrosative stress. GSNOR knockout mice have increased cellular amounts of both 
SNOs and GSNO (Liu, Hausladen et al. 2001; Liu, Yan et al. 2004). There appears to 
exist a transnitrosylation equilibrium between S-nitrosoglutathione GSNO and other 
SNOs (Gaston, Reilly et al. 1993). 
  More enzymes with denitrosylase activity have been reported. For instance 
xanthine oxidase (XO) is a flavoprotein enzyme containing iron and molybdenum and 
playing an important role in the catabolism of purines. XO facilitates the oxidation of 
hypoxanthine to xanthine and further of xanthine to uric acid. In the presence of purine 
or pteridine substrates, XO induces S-nitrosoglutathione (GSNO) decomposition 
(Trujillo, Alvarez et al. 1998)). The reduction of GSNO leads to the formation of GSH 
and •NO accompanied by peroxynitrite formation (Trujillo, Alvarez et al. 1998):  
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GSNO + ∙O2
- 
 
 
 + H
+→ GSH + •NO + O2 
O2
- + •NO → ONOO- 
 
The enzyme family of glutathione peroxidases (GPs) can be split up into two 
groups, selenium-independent and selenium-dependent enzymes. The selenium 
dependent GP group can decompose H2O2 (Kinnula, Crapo et al. 1995) by the 
glutathione redox cycle (Chance, Sies et al. 1979) which is responsible for capturing 
alkyl hydroperoxides. Selenium-dependent glutathione peroxidase 1 was found to 
catalyse the decomposition of GSNO in both presence and absence of different thiols to 
liberate NO (Hou, Guo et al. 1996). 
Superoxide dismutase (SOD) is the enzyme catalysing the dismutation of 
superoxide into hydrogen peroxide and oxygen and thus serves a key antioxidant role. 
Three SODs are distinguished by different metal content. The copper-containing 
enzymes have been shown to catalyse •NO release from GSNO (Singh, Hogg et al. 
1999).  
Protein disulphide isomerase (PDI) is an abundant protein found in the lumen of the 
endoplasmic reticulum of eukaryotic cells. The major role of PDI is the formation and 
rearrangement of disulphide bonds in proteins. PDI contains two segments with 
homology to thioredoxin and belongs to the Trx superfamily. PDI was found to break 
GSNO bonds (Sliskovic, Raturi et al. 2005). 
Carbonyl reductase1 (CBR1) efficiently reduces GSNO. This reduction is discussed 
in the “CBR1 and S-nitrosoglutathione reduction” chapter. 
SNOs are usually very unstable in aqueous solution, i.e. S-nitrosocysteine has a 
half-life of less than 2 min, but surprisingly, GSNO undergoes decomposition over 
hours (Singh, Wishnok et al. 1996). The decomposition of GSNO does not occur 
spontaneously, presence of additional agents such as light, metal ions, heat, thiols or 
reducing agents is needed. Thiols can decay GSNO by two mechanisms. First, the faster 
mechanism is reversible transnitrosylation,    
 
RSH + GSNO ↔ RSNO + GSH 
 
whereas the second is S-thiolation, the reduction of GSNO by a thiol to generate a 
nitroxyl anion and a mixed disulphide (Zeng, Spencer et al. 2001). An example of the 
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second mechanism is decomposition of GSNO by GSH, an important determinant of the 
intracellular redox state (Schmidt, Grey et al. 1996).  
 
GS
- + GSNO → GSSG + NO- 
 
A non-thiol GSNO reducing agent is ascorbic acid (Kashiba-Iwatsuki, Yamaguchi 
et al. 1996), which is specific for S-NO cleavage. 
GSNO plays an important and dual role in apoptosis, where it can serve either as 
inducer or inhibitor (Sandau and Brune 1996). Particularly, the neuroprotective effect of 
GSNO against oxidative stress has been shown (Inoue, Akaike et al. 1999). Another 
role of GSNO is inhibition of platelet activation and vasodilation (de Belder, 
MacAllister et al. 1994). Moreover, S-nitrosothiols are strong endogenous 
bronchodilators depleted in asthmatic airway lining fluid (Wu, Romieu et al. 2007). 
 
 
 
Figure 5: Structure of GSNO 
 
2.4.5 S-glutathionylation 
 
S-glutathionylation is another type of modification of the highly reactive Cys 
residues in proteins occurring both at physiological and non-physiological conditions. It 
implies the reversible formation of a disulphide bond between glutathione and a Cys 
thiol of the target protein (Thomas, Poland et al. 1995; Cotgreave and Gerdes 1998). 
GSH is a tripeptide, present in mammalian cells at concentrations that range between 1 
and 10 mM (Tietze 1969) and containing a reactive cysteine thiol, which maintains 
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proteins in their reduced state. Moreover, it protects cell from oxidative  stress and plays 
an important role in post-translational regulations of protein functions (Castellano, 
Ruocco et al. 2008). In presence of oxidative agents, two molecules of GSH can interact 
and form glutathione disulphide (GSSG).  
It is suggested that S-glutathionylation may occur either by reaction of the 
reduced protein cysteine with glutathione disulphide (GSSG), or, alternatively, 
independent of GSSG formation by the reaction of an oxidatively activated protein thiol 
with GSH (Klatt and Lamas 2000). Not all cysteines in one protein can be 
S-glutathionylated; the reaction requires specific Cys orientation and is enhanced by 
basic neighbouring residues. Increased GSSG levels have been presumed as the leading 
mechanism for S-glutathionylation (Martinez-Ruiz and Lamas 2007) and occur in 
diseases related to oxidative stress (Giustarini, Milzani et al. 2005) such as 
cardiovascular, lung and neurodegenerative diseases or cancer (Mieyal, Gallogly et al. 
2008). But GSSG is not the only S-glutathionylating agent. The reaction between 
GSNO and protein sulphydryls can also cause S-glutathionylation (as well as S-
nitrosylation).  
The mechanism of GSNO-mediated glutathionylation includes the homolytic 
cleavage of the S-NO bond producing •NO and thiyl (GS•) radicals (Mohr, Hallak et al. 
1999). The thiyl radical can cause the formation of protein disulphides (protein-SSG). 
The homolytic cleavage of GSNO can be facilitated if the cysteine thiol in the target 
protein is activated by proximity to a basic amino acid, e.g. histidine. The activated thiol 
is a strong nucleophile while not activated thiols are less nucleophilic and their potential 
to destroy an S-NO bond is not powerful enough. They rather prefer to be  
S-nitrosylated. Therefore the nucleophilicity of cysteine residues is responsible for the 
GSNO type of modification (Mohr, Hallak et al. 1999).   
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3 AIM OF THE THESIS 
 
 to prepare the desired mutants of CBR3 with selected changes incorporated in 
the sequence  
 to clone these mutants together with CBR1 and CBR3 wild types into the 
plasmid vector pET-28b(+) 
 to overexpress CBR1, CBR3 and the mutants into proteins and purify these 
proteins 
 to study the effect of GSNO on CBR1, CBR3 and all overexpressed mutants and 
determine kinetic properties 
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4 MATERIAL 
 
4.1 Chemicals 
 
Acetic acid  Sigma, Steinheim (Germany) 
Acetone Merck, Darmstadt (Germany) 
Agar  Sigma, Steinheim (Germany) 
Agarose Biozym Plague Genetic Pure Biozym, Hessisch-Oldendorf (Germany) 
Agarose NEEO Ultra Qualität  Carl Roth, Karlsruhe (Germany) 
Ampicillin AGS, Heidelberg (Germany) 
Ascorbic acid Merck, Darmstadt (Germany) 
Bovine serum albumin Behringwerke, Marburg (Germany) 
Bradford reagent Sigma-Aldrich, München (Germany) 
Calcium chloride dihydrate  Merck, Darmstadt (Germany) 
Coomassie Serva, Heidelberg (Germany) 
Copper (II) chloride 97 % Sigma-Aldrich, München (Germany) 
Dipotassium hydrogen phosphate 
dihydrate 
Merck, Darmstadt (Germany) 
Dithiothreitol  Sigma, Steinheim (Germany) 
dNTPs  Promega, Madison (USA) 
DTPA Sigma-Aldrich, München (Germany) 
EDTA  Sigma, Steinheim (Germany) 
Ethanol  Carl Roth, Karlsruhe (Germany) 
Glutathione Sigma-Aldrich, München (Germany) 
Glycerol 87 % Carl Roth, Karlsruhe (Germany) 
Hydrochloric acid Merck, Darmstadt (Germany) 
Imidazole  Merck, Darmstadt (Germany) 
IPTG  Peqlab Biotechnologie, Erlangen 
(Germany) 
Isopropyl alcohol  Merck, Darmstadt (Germany) 
Kanamycin  Alexis-Biochemicals, Lörrach (Germany) 
LB Broth  Miller Fisher Scientific, Schwerte 
(Germany) 
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Lysozym Sigma-Aldrich, München (Germany) 
MgCl2 Fermentas, St. Leon-Rot (Germany) 
N-1-naphthylethylenediamine Sigma-Aldrich, München (Germany) 
NADPH Carl Roth, Karlsruhe (Germany) 
PIPES Sigma-Aldrich, München (Germany) 
Potassium dihydrogenphosphate Merck, Darmstadt (Germany) 
Sodium dihydrogenphosphate 
monohydrate  
Promega, Mannheim (Germany) 
Sodium hydroxide  Merck, Darmstadt (Germany) 
Sodium chloride  Baker, Griesheim (Germany) 
Sodium nitrite Merck, Darmstadt (Germany) 
Sulphanilamide Sigma-Aldrich, München (Germany) 
Tris Base  Sigma, Steinheim (Germany) 
 
4.2 Enzymes  
 
KpnI  NEB, Frankfurt a. M. (Germany) 
T4 DNA Ligase NEB, Frankfurt a. M. (Germany) 
T4 DNA Polymerase  Fermentas, St. Leon-Rot (Germany) 
XhoI  NEB, Frankfurt a. M. (Germany) 
TEV protease Zoologisches Institut - Strukturbiologie 
Zentrum für Biochemie und 
Molekularbiologie  
Christian-Albrechts-Universitaet zu Kiel 
Taq Polymerase QIAGEN, Hilden (Germany) 
 
4.3 Bacterial strains 
 
E.coli HB101 strain Amersham Biosciences, Freiburg 
(Germany) 
E. coli BL21 (DE3) strain Novagen, Merck, Darmstadt (Germany) 
E. coli Origami strain Novagen, Merck, Darmstadt (Germany) 
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4.4 Oligonucleotides 
 
All PCR primers  
 
MWG, Ebersberg (Germany) 
4.5 Plasmids 
 
pET-28b(+) Novagen, Merck, Darmstadt (Germany) 
 
4.6 Kits 
 
Illustra TempliPhi 100 Amplification Kit  GE Healthcare, Buckinghamshire (UK) 
QIAEX II Gel Extraction Kit QIAGEN, Hilden (Germany) 
QIAGEN Plasmid Midi Kit QIAGEN, Hilden (Germany) 
QIAquick Gel Extraction Kit QIAGEN, Hilden (Germany) 
QIAexpress Kit QIAGEN, Hilden (Germany) 
 
 
4.7 Consumables 
 
96-well microtest plates  Sarstedt, Nürnbrecht (Germany) 
Amicon
®
 Ultra-4 centrifugal filter device Millipore, Billerica (USA) 
Eppendorfs Sarstedt, Nürnbrecht (Germany) 
PD-10 Desalting columns Amersham Biosciences Freiburg 
(Germany) 
Disposable cuvettes  Sarstedt, Nümbrecht (Germany) 
Pipette tips (every range of volume)  Sarstedt, Nümbrecht (Germany) 
Ready Bis-Tris gels (gradient 4-12 %)  Invitrogen, Karlsruhe (Germany) 
Sterile filter  Millipore, Billerica (USA) 
Petri dishes Sarstedt, Nümbrecht (Germany) 
Multiply PCR cups 0.2 ml  Sarstedt, Nürnbrecht (Germany) 
Multiply-μStrip of 8 tubes 0.2 ml Sarstedt, Nürnbrecht (Germany) 
 
4.8 Markers and stains 
 
6× Loading Dye Solution  Fermentas, St. Leon-Rot (Germany) 
Gene Ruler 100 bp DNA Ladder Plus  Fermentas, St. Leon-Rot (Germany) 
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Protein Molecular Weight Marker  Fermentas, St. Leon-Rot (Germany) 
SYBR Safe DNA Gel Stain  Invitrogen, Karlsruhe (Germany) 
  
4.9 Equipment 
 
Analytical balance R1605 Sartorius, Göttingen (Germany) 
Autoclave Systec tuttnauer 
2540EL 
Systec, Wettenberg (Germany) 
Centrifuges Biofuge pico 
Biofuge fresco 
Biofuge 15R 
Megafuge 11R 
J2-HS  
Heraeus, Hanau (Germany) 
 
 
 
Beckman, 
Krefeld (Germany) 
Electrophoresis power 
supply 
Power pack 300 
 
Power Pack 35/60  
Bio-Rad Laboratories, München 
(Germany) 
Phase, Lübeck (Germany) 
Gel documentation 
system  
 
 
Image Master VDS + 
FUJIFILM 
Imaging System FTI-
500 
Gel IX Imager 
NU-72 
Pharmacia Biotech, Freiburg 
(Germany) 
 
 
Intas, Göttingen (Germany) 
Benda, Weisloch (Germany) 
Gel electrophoresis 40-1214 
40-0911 
PEQLAB Biotechnologie, Erlangen 
(Germany) 
Heating blocks Thermomixer 5436 
Thermoblock TB2 
Eppendorf, Hamburg (Germany) 
Biometra, Göttingen (Germany) 
Incubator B6030 Heraeus, Hanau (Germany) 
 
Incubator 
 
TH 15, KS 15 
 
Edmund Bühler, Hechingen 
(Germany) 
Microplate reader  Tecan, Männedorf (Switzerland) 
Multipipette Multipipette Plus Eppendorf, Hamburg (Germany) 
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Nickel affinity 
chromatography  
Äkta-Purifier  GE Healthcare, New Jersey (USA) 
1 ml Ni-NTA columns  GE Healthcare, New Jersey (USA) 
PCR Thermocycler T-Gradient  
T- profesional 
Biometra, Göttingen (Germany) 
pH meter pH 535 Multical WTW, Weilheim (Germany)  
Pipettes 1-10 µl 
2-20 µl 
20-200 µl 
100-1000 µl 
Eppendorf, Hamburg (Germany) 
Gilson, Middleton (USA) 
Precision balance BP3100S Sartorius, Göttingen (Germany) 
Rocking platform  VWR VWR International, Darmstadt 
(Germany) 
SDS PAGE XCell SureLock Invitrogen, Karlsruhe (Germany) 
Sonicator Sonoplus UW2200  Bandelin, Berlin (Germany) 
Spectrophotometer GeneQuant II Pharmacia Biotech, Freiburg 
(Germany) 
Vacuum concentrator SPD121P SpeedVac Thermo, Egelsbach (Germany) 
Ultracentrifuge  TGA-65 Kontron Analytical, (Schwitzerland) 
Vortex  VF2 Ika, Staufen (Germany) 
      
4.10 Software 
 
ACD/ChemSketch Advanced Chemistry Development, 
Toronto (Canada) 
Cary WinUV Varian, Palo Alto (USA) 
EndNote Thomson Reuters, New York (USA) 
FinchTV Geospiza, Seattle (USA) 
Gel IX Imager Intas, Göttingen (Grmany) 
Geneious Biomatters, Auclkand (New Zealand) 
GraphPad Prism GraphPad Software, La Jolla (USA) 
PyMOL open source foundation 
XFluor Tecan, Männedorf (Switzerland) 
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5 METHODS 
 
5.1 Mutagenesis and cloning 
 
5.1.1 Polymerase chain reaction (PCR) 
 
PCR is a technique to amplify a piece of DNA generating thousands to millions 
of copies of the original sequence of the DNA molecule. PCR is based on the ability of 
a thermostable DNA polymerase to replicate a new strand of DNA complementary to 
the offered DNA template strand. In fact, any piece of DNA can be amplified into 
millions of identical copies as is shown in Figure 6. The method was established in 
1984 by Kary Mullis who was awarded the Nobel Prize in Chemistry in 1993 for this 
work. PCR relies on thermal cycling, consisting of repeated heating and cooling cycles. 
Three major steps are involved in one PCR cycle. Each step, denaturation, annealing, 
and extension takes place at a different temperature. The first step, denaturation of the 
DNA, involves heating to 95°C, which dissociates the target DNA into two strands. In 
the second step, primers containing sequences complementary to the target region bind 
to the single strand generated in the previous PCR step. This annealing is proceeding at 
about 54°C. In the third step at about 72°C a thermostable DNA polymerase which can 
sustain high temperature moves along the DNA, reading its code and synthesising a 
copy. The general composition of PCR mixtures as used in this work is given in 
Table 1. 
 
PCR requires the following conditions:  
 
 MgCl2 necessary for DNA polymerase activity, provided at a concentration of 
0.5 to 2.5 mM 
 buffer providing a suitable chemical environment for DNA polymerase  
 dNTPs at a concentration of 20 to 200 µM,  the structural elements from which 
the DNA polymerase synthesises a new DNA strand  
 two primers (forward and reverse) at a concentration of 0.1 to 0.5 µM 
 thermostable DNA Polymerase  
 target DNA to be amplified at an amount smaller than 1 µg 
 monovalent cations 
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Figure 6: The exponential amplification of the gene in PCR  
 (http://users.ugent.be) 
 
Table 1: General composition of 20 µl and 50 µl PCR reaction mixture used in this work 
 
component  volume  component  volume   
Taq polymerase (5 U/µl)   0.4 µl  Taq polymerase (5 U/µl)   1 µl 
template   1 µl  template   1 µl 
dNTPs (10 mM each)   0.4 µl  dNTPs (10 mM each)   1 µl 
forward primer (100 pmol/µl)   0.4 µl  forward primer (100 pmol/µl)   1 µl 
reverse primer (100 pmol/µl)   0.4 µl  reverse primer (100 pmol/µl)   1 µl 
Taq polymerase buffer   2 µl  Taq polymerase buffer   5 µl 
MgCl2 (15 mM)   1.5 µl  MgCl2 (15 mM)   4 µl 
water 13.9 µl  water 36 µl 
total volume 20 µl  total volume 50 µl 
  
  
 The PCR temperature cycles are usually repeated 20-40 times. A variety of 
parameters influence the conditions such as the temperatures used and the length of 
each cycle kept during PCR. The PCR condition determinanting factors: the enzyme 
used for DNA amplification, the concentration of Mg
2+
 ions and dNTPs in the reaction 
and the melting temperature of the primers. Thermo cycler conditions which were used 
for all assays are indicated in Table 2. The denaturation, annealing and extension step 
was repeated 30 times. 
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Table 2: Thermo cycler conditions during PCRs repeated 30 times 
 
step duration temperature  
initial denaturation   1 min  95°C  
denaturation   1 min 95°C  
annealing   1 min /kb 55°C repeated 30x 
extension   1 min 72°C  
final extension 10 min 72°C  
 
 
5.1.2 Mutagenesis by splicing by overlap extension (SOE) 
 
Gene splicing by overlap extension (SOE) is a sequence-independent technique 
used for site-directed mutagenesis and recombination of DNA molecules. The idea is 
based on adding or changing sequences at the end of a PCR product, so the product can 
serve as a new primer for a subsequent overlap-extension reaction, which enables 
insertion of mutations at specific positions in a sequence (Ho, Hunt et al. 1989; Horton 
1995).  
Two fragments of the target sequence are amplified in two separate PCR 
reactions as outlined in Figure 7. For each reaction one primer outside the region to be 
mutated and one mutagenic primer are used, the latter carrying the desired change in 
sequence. The two created intermediate PCR fragments comprise complementary ends 
formed by the mutagenic primers and can create a new DNA template by overlapping in 
a subsequent PCR to yield the recombinant product. During this extension the two 
outside primers are used to initiate the synthesis of the new fused product (Ho, Hunt et 
al. 1989; Horton 1997). In principle, to introduce mutations by SOE, the position of the 
mutation has no limitation and can be introduced  anywhere along the targeted DNA 
(Vallejo, Pogulis et al. 1994). 
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Figure 7: Mutagenesis by overlap extension 
By PCR two segments of a DNA are amplified and then fused together in a subsequent reaction. Two 
specially designed mutagenic primers (b, c) enables to introduce the mutation forming complementary 
terminal regions of the intermediate PCR products. These regions can be fused by an overlap extension in 
a subsequent reaction.  The amplification of the fused recombinant mutant is carried out by the use of the 
two outside primers (a, d) (Vallejo, Pogulis et al. 1994).  
 
Several positions both in CBR1 and CBR3 were decided to be investigated. 
Some DNA fragments, already with incorporated mutated positions, were received from 
Yasser El-Hawari. The complete list of sequence mutations is given below in Table 6. 
In this thesis, efforts were made to replace positions Cys226 and Cys227 in CBR1 and 
Cys143 in CBR3 by Ser resulting in the mutants CBR1 Cys226Ser, CBR1 Cys227Ser 
and CBR3 Cys143Ser. In the first step 6 PCR reactions were run. Master Mix was 
prepared from double distilled water, Taq polymerase buffer, MgCl2, reverse and 
forward primers (see Table 3), dNTPs and Taq Polymerase, a thermostable DNA 
polymerase isolated from the bacterium Thermus aquaticus. As a template CBR1 and 
CBR3 already incorporated in pET-28b(+) vector were used. PCR products were 
analysed via agarose gel electrophoresis. 
 
 
37 
 
Table 3: Sequences of primers used for mutagenesis 
In yellow are restriction sites for KpnI, in red XhoI and in blue triplets coding changed amino acids 
 
PCR 
reaction 
number 
position to 
be 
changed 
primer sequence of the primer 
1 
CBR1 
Cys226Ser 
forward CTGTATCTGCAGGGTACCCCCGGGATGTCGTCCGGC 
reverse CACCCACCCTGGGCAGGAGGCATTCAGGAGGA 
2 
forward TCCTCCTGAATGCCTCCTGCCCAGGGTGGGTG 
reverse GACGACCTCGAGTCACCACTGTTCAAC 
3 
CBR1 
Cys227Ser 
forward CTGTATCTGCAGGGTACCCCCGGGATGTCGTCCGGC 
reverse TCTCACCCACCCTGGGGAGCAGGCATTCAGGAG 
4 
forward CTCCTGAATGCCTGCTCCCCAGGGTGGGTGAGA 
reverse GACGACCTCGAGTCACCACTGTTCAAC 
5 
CBR3 
Cys143Ser 
forward ATGATGGGTACCATGTCGTCCTGCAGCCGCGT 
reverse TTCAAAAGCCCTTAAAGACTGCAAACTACTGAT 
6 
forward ATCAGTAGTTTGCAGTCTTTAAGGGCTTTTGAA 
reverse GACGACCTCGAGTTACCAGTTTTGCACAAC 
 
 
5.1.3 Agarose gel electrophoresis 
 
Agarose gel electrophoresis is a method to separate DNA fragments according to 
their sizes and to visualize them. As DNA is negatively charged, in an electric field it 
moves through the gel matrix towards the positive pole. The gel matrix slows the DNA 
molecules down and smaller molecules migrate faster than larger molecules. Depending 
on the fragment size, 0.75 % to 2.0 % agarose gels are usually used. The DNA is 
visualized on a UV trans-illuminator by staining with a fluorescent dye. In the 
preparative approaches, i.e. when a band was to be excised and extracted from the gel 
for further procedures the wavelength 366 nm instead of 312 nm was used for 
visualization. This wavelength assures no damage of the DNA during UV-exposure. 
For separation an agarose concentration of 1 % (w/v) in 1 x TAE buffer (see 
Table 5) was used. To visualise the sample DNA SYBR
®
Safe, a stain for nucleic acids, 
was added according to the manufacturer's instruction. Before loading the gel with the 
PCR samples, each sample was mixed with 6 x Loading Dye Solution causing higher 
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density of the samples so that they sink to the bottom of the well. 10 µl of GeneRuler 
100 bp Plus was used to check the size of the PCR products. 
The appropriate DNA bands were excised from the gel and centrifuged through 
glass wool at 8.000 rpm for 10 min to remove the agarose. A flow through volume of 
1 µl was used as a template for the following PCR reaction (see Table 4). The three new 
constructs were purified via a preparative 1 % agarose gel electrophoresis and the 
Qiagen gel extraction kit. 
 
Table 4: Subsequent PCR reactions resulting in desired mutants  
Restriction sites for KpnI are displayed in yellow, XhoI in red. 
 
PCR 
reaction 
number 
position 
to be 
changed 
template 
(number 
of PCR 
reaction) 
primer sequence of the primer 
7 
CBR1 
Cys226Ser 
1, 2 
forward CTGTATCTGCAGGGTACCCCCGGGATG 
TCGTCCGGC 
reverse GACGACCTCGAGTCACCACTGTTCAAC 
8 
CBR1 
Cys227Ser 
3, 4 
forward CTGTATCTGCAGGGTACCCCCGGGATG 
TCGTCCGGC 
reverse GACGACCTCGAGTCACCACTGTTCAAC 
9 
CBR3 
Cys143Ser 
5, 6 
forward ATGATGGGTACCATGTCGTCCTGCAGC 
CGCGT 
reverse GACGACCTCGAGTTACCAGTTTTGCAC 
AAC 
 
 
Table 5: Composition of 40 x TAE buffer, pH 8.0 
 
component concentration amount 
Tris 40.0 mM      121 g 
100 % acetic acid 40.0 mM        28.6 ml 
0,5 M Na2EDTA   1.0 mM          1 ml 
H2O  ad 500 ml 
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5.1.4 Gel extraction and purification of DNA 
 
The QIAquick Gel Extraction Kit Protocol using a microcentrifuge was followed 
for DNA preparation. All centrifugation steps were carried out at 13.000 rpm at room 
temperature. DNA fragments were excised from the preparative agarose gel, weighed 
and three volumes of Buffer QG were added to one volume of gel. To dissolve the gel, 
the gel pieces were incubated at 50°C for 10 min. Next, one volume of isopropanol was 
added. To bind the DNA, the samples were applied to the QIAquick column and 
centrifuged for 1 min. To dispose of all agarose traces 0.5 ml of Buffer QG was added 
to the column and centrifuged again for 1 min. The columns were washed with 0.75 ml 
of Buffer PE and centrifuged twice for one min to remove all residual ethanol. DNA 
was eluted with 40 µl of Buffer EB. All buffer compositions are described in the 
manufacturer´s instructions.  
 
5.1.5 Measuring DNA concentration 
 
Concentration and quality of a sample of DNA were measured by the 
GeneQuant II UV spectrophotometer. The aromatic rings of the bases in DNA absorb 
UV light with an absorption maximum at 260 nm. Proteins absorb ultraviolet light at 
280 nm, largely due to the aromatic tryptophan ring. If there is a protein contaminant, 
there is additional OD280 which decreases the OD ratio between 260 and 280 nm. 
Clean DNA has an OD260/OD280-ratio between 1.8 and 2.0. A smaller value indicates 
a contamination.   
 
5.1.6 Digestion of DNA fragments and pET-28b(+) vector 
 
Restriction endonucleases are enzymes found in bacteria that cleave the  
sugar-phosphate backbone of DNA at specific recognition nucleotide sequences termed 
restriction sites. Several hundred different restriction endonucleases have been isolated. 
Besides the fragments which were constructed in this thesis, additional constructs 
together with CBR3 wild type (CBR3wt) fragment were kindly provided by Yasser El-
Hawari in the form of undigested PCR products or already incorporated in the vector 
pET-15b(+). CBR1 already incorporated in a modified version of the pET-28b(+) vector 
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(see appendix) was kindly provided by Claudia Staab. For the complete list and form of 
inserted mutations see Table 6. 
PCR fragments with desired mutations, CBR3wt and pET-28b(+) were double 
digested by restriction endonucleases KpnI and XhoI (New England Biolabs, NEB). The 
reaction mixture (see Table 7) of a total volume of 20 µl was prepared and incubated for 
60 min at 37°C in a heat block. As restriction endonucleases are supplied in 50 % 
glycerol, the addition of restriction enzymes should not exceed 10 % of the total volume 
to avoid star activity (alteration of the specificity of restriction enzyme) caused by 
glycerol. The purification of the fragments is required to avoid possible interferences of 
reaction compounds with subsequent reactions. 
 
Table 6: Positions changed by mutagenesis 
For CBR1 and CBR3 sequence alignment see Figure 4. 
 
mutant  
positions of CBR3 
changed to correspond 
to CBR1 
source and form of the 
fragment 
 
CBR3wt none  
provided by Yasser  
El-Hawari as undigested 
PCR product 
 
K106Q 106 
SUMU 
142,143, 230, 236-244, 
270 
97VA 97, 98 
SOE 236-244 provided by Yasser  
El-Hawari incorporated 
into pET-15b(+) vector 
 
SOE P230W 230, 236-244 
Cys143Ser 143 constructed in this thesis 
 
positions of CBR1 
changed to Ser 
 
CBR1wt none 
provided by Claudia Staab 
incorporated into  
pET-28b(+) vector 
Cys226Ser 226 
constructed in this thesis 
Cys227Ser 227 
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Table 7: Composition of digesting reaction mixture  
Component Volume 
BSA (1 mg/ml)   2 µl 
NEB buffer 1 (10x)   2 µl 
DNA fragment   5 µl 
H2O   9 µl 
KpnI (10 U/µl)   1 µl 
XhoI (20 U/µl)   1 µl 
Total volume 20 µl 
 
 
5.1.7 Purification of DNA fragments and pET-28b(+) vector 
 
Purification of digested fragments was carried out according to the QIAEX II 
Protocol. The QIAEX II Gel Extraction Kit is designed for purification and 
concentrating DNA fragments from 40 bp to 50 kb from aqueous solutions with no 
demand for using phenol extraction or ethanol precipitation. Enzymes such as 
restriction endonucleases, polymerases, phosphatases, as well as dNTPs and salts are 
removed. 60 µl of Buffer QX1 was added to 20 µl of samples and the colour of the 
mixtures turned yellow. QIAEX II solution was mixed by vortexing for 30 sec and 10 µl 
was added to the samples. The mixtures were incubated 10 min at room temperature 
while mixing every 2 minutes to keep QIAEX II in suspension. After that, the samples 
were centrifuged for 30 sec at (max) 10.000 x g and the supernatants removed. The 
pellets were washed twice with 500 µl of Buffer PE and air-dried for 15 min. DNA was 
eluted by 20 µl of 10 mM Tris, pH 8.5, vortexed shortly and incubated for 5 min at 
room temperature. Pure DNA was obtained by centrifuging the sample for 30 sec at 
(max) 10.000 x g. The supernatants contained the desired pure DNA.  
Digested pET-28b(+) vector was purified via preparative agarose gel 
electrophoresis and the Qiagen gel extraction kit, as described under “Gel extraction and 
purification of DNA”. The Concentration of all samples was measured by the 
GeneQuant II UV spectrophotometer.  
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5.1.8 DNA Ligation 
 
 During DNA ligation, two linear DNA molecules are joined together by 
creating a covalent bond from the 3' hydroxyl of one nucleotide and the  
5' phosphate of the other. This reaction is catalysed by a DNA ligase. T4 DNA ligase 
from the T4 bacteriophage is the most common used DNA ligase for molecular biology 
techniques.  
A ligation reaction requires: 
 
 two or more fragments of DNA  
 a buffer containing ATP 
 T4 DNA ligase 
 
The Rapid DNA Ligation kit was used for ligation. Accurate amounts of 
digested and purified vector and fragments to be inserted were mixed. The 
recommended amount of the vector, which was also used in this thesis, is 50 – 100 ng 
per reaction. The ligation mixture contained 3 fold molar access of foreign DNA 
relative to the vector. 4 µl of 5 x rapid ligation buffer, H2O up to 9 µl and finally 1 µl of 
T4 DNA ligase were added into each tube. Mixtures were incubated overnight at 18°C. 
 
5.1.9 Preparation of E. coli HB101 and BL21 strain competent cells 
 
Considering the high hydrophilicity of the DNA molecule, the DNA is not able to 
pass through the bacterial cell membrane. The ability of a bacterial cell to take up 
extracellular DNA is called cell competence. Competence is distinguished into the 
natural competence and induced competence which arises during treating cells in 
laboratory cultures to make them permeable to DNA. In the present thesis, the calcium 
method was used to generate competent cells where a high calcium concentration 
creates small holes in the bacterial cell wall. Two E. coli strains were made competent, 
first, the E. coli HB101 strain, a non-expression host with resistance to streptomycin, 
which is suitable for routine cloning and second, the E. coli BL21 strain, an expression 
host for any gene, which is under control of a T7 promoter. The BL21 strain has no 
antibiotic resistance.   
A starter culture of 2 ml LB medium was inoculated with a glycerol stock of 
HB101 or BL21 E. coli strains and incubated overnight in a shaker (200 rpm) at 37°C. 
43 
 
The next day, this culture was used to inoculate 250 ml sterile LB medium. The culture 
growth at 37°C and 200 rpm was observed to determine the mid-exponential growth 
phase, which is most suitable to make cells competent  
When the optical density of the cell culture measured at 595 nm had reached 
about 0.4 – 0.5, the cultures were cooled on ice and centrifuged at 3.000 x g for 10 min 
at 4°C. The pellet was resuspended in 100 ml ice-cold sterile CaCl2 solution (60 mM 
CaCl2, 15 % glycerol, 10 mM PIPES, pH 7) and spun down at 3.000 x g for 10 min at 
4°C. The resuspension and centrifugation step was repeated and the pellet was finally 
resuspended in 10 ml of ice-cold sterile CaCl2 solution. The competent cells were 
aliquoted into prechilled tubes, snap-frozen in liquid nitrogen and stored at – 80°C. 
 
5.1.10 Transformation  
 
In the context of molecular biology, transformation is the genetic modification 
of a bacterium by the uptake and incorporation of exogenous DNA. Thus a foreign 
plasmid or a ligation product can be inserted into bacteria. The host cells will then 
replicate the foreign DNA along with their own.  The condition is that the plasmid DNA 
that entered the cell must contain an origin of replication recognized by the host cell 
DNA polymerases. Plasmids used for transformation experiments usually also contain a 
gene conferring resistance to an antibiotic that the intended recipient bacterial strain is 
sensitive to. The selection of cells which have been transformed by the plasmid is then 
achieved by the ability to grow on media containing this antibiotic. 
  Transformation of plasmid DNA into CaCl2-competent E. coli was performed 
using the heat shock method. 5 µl of ligation mixtures were added into 100 µl E. coli 
HB101 competent cells and the mixtures were incubated for 30 min on ice water. 
Subsequently the heat-shock step at 42°C for 90 sec in a heat block was carried out, 
directly followed by 3 min incubation on ice water. The heat-shock step causes 
depolarisation of the cell membrane treated with CaCl2. The decreased membrane 
potential may reduce the negatively charged environment inside the cell and support the 
movement of negative DNA through the cell membrane. A subsequent cold-shock 
restores the membrane potential back to its original condition. After this, 500 µl of 37°C 
warm LB medium was added and the mixtures were incubated at 37°C under shaking 
for one hour and plated on agar plates containing kanamycin at a concentration of 
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25 µg/ml. The agar plates were left for approximately 30 min to soak up the medium 
and then incubated overnight with the bottom up at 37°C.  
 
5.1.11 Picking colonies, culturing and PCR 
 
 An appropriate volume of LB medium with kanamycin (25 µg/ml, LB+KAN) 
was prepared. The clones grown were picked (2-3 colonies per construct) with a sterile 
tip and used for inoculating 500 µl of LB+KAN medium. These inoculated solutions 
served as precultures for later bigger cultures for plasmid preparation. The lids of the 
eppendorf tubes were perforated to allow for oxygenation and the cultures were 
incubated overnight at 37°C in a shaker. To check for the correct insertion of fragments 
into the vector during ligation, a PCR was run. As a template 1 µl from 500µl overnight 
precultures was taken. 1 µl of pET-15b(+) vector with incorporated CBR3 (provided by 
Yasser El-Hawari) sequence or 1 µl of CBR1 incorporated in pET-28b(+) (provided by 
Claudia Staab) were taken as a positive control. 5´- CBR3 and 3´- CBR3 fragments 
served as primers for CBR3 mutants, 5´- CBR1 and 3´- CBR1 primers were used for 
CBR1 mutants (for primer sequences see Table 8). The composition of the master mix 
for the reaction volume of 20 µl per reaction and PCR conditions were kept the same as 
listed in Tables 1 and 2. 
 
Table 8: Sequences of primers used for PCR 
 
primer sequence of the primer 
5´- CBR3   ATGTGCTCCTGCAGCCGGGTG       
3´- CBR3   CCAGTTTTGCACAACTTTGTC 
5´- CBR1 ATGTCGTCCGGCATCCAT 
3´- CBR1 TCACCACTGTTCAACTCTCTTCTC 
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5.1.12 Plasmid preparation 
 
Plasmids were purified according to the QIAGEN Plasmid Midi Protocol. 
100 ml LB + KAN was inoculated with 100 µl of overnight precultures and cells were 
grown overnight at 37°C under shaking. After that, the bacterial cells were harvested by 
centrifugation at 6.000 x g for 15 min at 4°C. The pellets were resuspended in 4 ml 
Buffer P1. 4 ml of Buffer P2 were added; the solutions were mixed and incubated 5 min 
at room temperature. In the next step 4 ml of prechilled Buffer P3 were added followed 
by 15 min incubation and centrifugation at 20.000 x g for 30 min at 4°C. Supernatants 
containing plasmid DNA were removed promptly, centrifuged again at 20.000 x g for 
15 min at 4°C and applied to the QIAGEN-tips 100 previously equilibrated with 4 ml of 
Buffer QBT. The QIAGEN-tips were washed with 2 x 10 ml of Buffer QC. DNA was 
eluted with 5 ml Buffer QF, precipitated by 3.5 ml of room temperature isopropanol and 
subsequently centrifuged at 15.000 x g for 30 min at 4°C. DNA pellets were washed 
with 2 ml of room temperature 70 % ethanol and centrifuged again at 15.000 x g for 10 
min at 4°C. Supernatants were removed and the pellets were air-dried for 10 min. 
Finally the DNA was redissolved in 100 µl of elution buffer (10 mM Tris-HCl, pH 8.5). 
Concentrations of samples were measured by the GeneQuant II UV spectrophotometer.      
     
5.1.13 Rolling circle amplification 
 
The TempliPhi™ DNA Sequencing Template Amplification Kit, which was used 
in this assay, has been developed specifically to prepare templates for DNA sequencing. 
The TempliPhi method utilizes bacteriophage 29 DNA isothermal polymerase enzyme 
to exponentially synthesize multiple copies of circular molecules of DNA templates by 
rolling circle amplification (RCA) (Nelson, Cai et al. 2002).  In RCA, a circle of DNA, 
random hexamer primers and a polymerase enzyme catalyst converts dNTPs into DNA 
molecule. Unlike other amplification procedures, RCA produces an amplified product 
that remains linked to the DNA primer (Nallur, Luo et al. 2001). The proofreading 
activity of 29 DNA polymerase ensures high fidelity of DNA replication. Using this 
amplification method (Figure 8), picogram amounts of sample are sufficient to obtain 
microgram quantities of product. Depending on the source of starting material, 
amplification is completed in 4–18 hours at 30˚C with no need for thermal cycling. The 
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synthesised DNA can be used directly for sequencing reactions without any need for 
further purification. 
TempliPhi Kit components including sample buffer and reaction buffer were 
thawed on ice. Volume aliquots corresponding to 1 pg to 10 ng of DNA were added into 
the tubes containing 5 µl of sample buffer. Samples were denatured at 95°C for 3 min 
and then cooled to room temperature. The TempliPhi premix was prepared from 5 µl of 
reaction buffer and 0.2 µl of enzyme mix for each TempliPhi reaction. This premix 
contains all components necessary to generate the nonspecific amplification product, 
and must be kept on ice. 5 µl of TempliPhi premix were added to each cooled denatured 
sample and mixtures were incubate at 30°C for 5-18 hours.  The enzyme was heat-
inactivated at 65°C for 10 min and cooled to 4°C after. 
 
 
 
 
Figure 8: Mechanism of rolling circle amplification  
(Fujii, Kitaoka et al. 2006) 
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5.1.14 Sequencing 
 
The plasmid DNA synthesised by RCA was sequenced by the "Institute of 
Clinical Molecular Biology (ICMB)" in the "University Medical Centre Schleswig-
Holstein" or "Eurofins MWG Operon". pLIC forward primer and pLIC reverse primer 
(see Table 9 for sequences) were used for initiating the reading reaction. The obtained 
sequences were checked against the known sequences from databases with the "Finch 
TV" programme (Geospiza). Sequence alignments were made using the bioinformatic 
tools “Nucleic Acid Sequence Massager” and “ClustalW”. If the complete identity with 
the corresponding sequence from databases was confirmed, it was used for further 
experiments. 
 
Table 9: Sequences of primers used for sequencing 
 
primer sequence of the primer 
pLIC forward TGTGAGCGGATAACAATTCC 
pLIC reverse  AGCAGCCAACTCAGCTTCC 
 
 
5.2 Overexpression and purification of proteins 
 
5.2.1 Overexpression 
 
To overexpress protein in high quantity the lac operon induction method in 
combination with the pET vector expression system (Novagen) was used. The protein 
coding sequences were cloned into pET-15b(+) or a slightly modified pET-28b(+) 
vector which both exhibit the lac operon upstream of the multiple cloning site. In the 
absence of lactose, a repressor binds to the operator, inhibiting RNA polymerase from 
transcribing the genes that are under the control of the lac operon. When the inducer, 
lactose or an analogue, is added, it binds to the repressor and changes the repressor's 3D 
structure so the repressor is released from the operator and the transcription can start. In 
the pET vector system, the gene of interest is under the control of a T7 RNA 
polymerase promoter. When activated, e.g. by IPTG, the cells start to synthesise T7 
RNA polymerase and the transcription of desired gene proceeds rapidly, followed by 
protein translation.  Both the T7 promoter and the T7 polymerase do not occur naturally 
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in any procaryotic organism. Most of the pET expression vectors also encode  
N-terminal 6xHis fusion tags which can be used for further protein purification by 
immobilized metal affinity chromatography.  
The pET-28b(+) and the pET-15b(+) vector expression constructs were 
transformed into E. coli BL21 strain. Because of the different plasmid-coded antibiotic 
resistances, for pET-28b(+) vector kanamycin-containing (25 µg/ml) agar plates, for 
pET-15b(+) vector ampicillin-containing (100 µg/ml) agar plates, were used as a culture 
medium. Clones from the transformation were picked for an inoculation of 5 ml of LB 
medium containing kanamycin (25 µg/ml) or ampicillin (100 µg/ml). The preparatory 
cultures were incubated overnight at 37°C in a shaker. These cultures were transferred 
into 200 ml of prewarmed LB medium containing kanamycin or ampicillin, again at the 
concentrations mentioned above. For the overexpression an optical density measured at 
595 nm of nearly 0.6 is required, therefore the culture was incubated at 37°C until this 
OD was reached. At this moment 400 µl 0.5 M IPTG were added. The cultures were 
grown for additional 4.5 hours. After that, the cell cultures were harvested by 
centrifugation at 6.000 x g for 15 min at 4°C, the supernatant was decanted and the 
pellets were frozen at -20°C until the next day.  
 
5.2.2 Cell lysis 
 
The pellets were thawed 15 min on ice and resuspended in 10 ml of 10 mM 
imidazol buffer (see Table 10). For breaking the bacterial cell walls 10 mg of hen egg 
white lysozyme was added and the suspension incubated for 30 min on ice. Lysozyme 
acts by catalyzing the hydrolysis of 1,4-β-linkages in peptidoglycans and chitodextrins 
in the bacteria cell wall.   
Efficient extraction is dependent on disrupting protein interactions to release 
proteins bound in macromolecular assemblies. Disruption of the cells by sonication was 
used here. Sonication is the process of converting an electrical signal into a physical 
vibration. In the solution, this powerful vibration evocates rupture of cells and 
disintegration of molecules. Since a huge amount of heat is produced, sonication must 
be performed on ice. Each sample was sonicated on ice 6 times for 10 s at 200 W. After 
sonication the samples were ultracentrifuged at 100.000 x g for 60 min at 4°C. The 
resulting supernatants were used for the following purification. 
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Table 10 : Composition of 10 mM imidazol buffer 
 
component  concentration amount 
NaH2PO4 . H2O    20 mM              2.76 g  
NaCl  500 mM            29.22 g  
Imidazol    10 mM             0.68 g 
Glycerol 87 %    10 %         115 ml 
H2O   ad 1.000 ml 
 
 
5.2.3 Protein purification 
 
 Protein purification was achieved by fast protein liquid chromatography (FPLC) 
using 1 ml Ni-NTA (nickel-nitrilotriacetic acid) affinity. It is based on the high-affinity 
binding of six consecutive histidine residues (the 6xHis tag) to immobilised nickel ions 
that allows purification of tagged proteins. Elution was achieved by competition with 
increasing concentration of imidazol buffer (see Table 11), which binds to Ni-NTA and 
displaces the tagged protein. An imidazol gradient from 10 - 500 mM in 30 min with a 
flow rate of 1.1 ml per minute was used. The protein peak was monitored at 280 nm and 
the peak fraction, eluted approximately at 30 mM imidazol, was collected.   
   
Table 11: Composition of 500 mM imidazol buffer 
 
component  concentration amount 
NaH2PO4 . H2O    20 mM            2.76 g  
NaCl  500 mM          29.22 g  
Imidazol  500 mM          34.04 g 
Glycerol 85 %    10 %        115 ml 
H2O   ad 1000 ml 
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5.2.4 Desalting and buffer exchange 
 
To eliminate all unwanted ions and rebuffer the samples, the GE Healthcare PD-
10 Desalting columns containing Sephadex™ G-25 Medium for group separation of 
high (Mr > 5.000) from low (Mr < 1.000) molecular weight substances, were used. First 
the columns were equilibrated with approximately 25 ml elution buffer (0.2 M 
potassium phosphate buffer, pH 7.4 in this case, see Table 12). After that, 2.5 ml of the 
samples were applied to the column. Finally, the protein was eluted with 3.5 ml of 
elution buffer.   
 
Table 12: Composition of 1 M potassium phosphate buffer stock solution adjusted to pH 7.4  
The solution was prepared from 500 ml of the basic solution and an aliquot of the acid solution needed to 
achieve pH 7.4.  
 
 component amount/volume pH 
acid 1 M KH2PO4   68.5 g/500 ml ca 4.2 
base 1 M K2HPO4 . 3H2O 114.1 g/500 ml ca 9.3 
 
 
5.2.5 Bradford method for determination of protein concentration 
 
The so-called Bradford assay is based on the observation that the absorbance 
maximum for an acidic solution of the dye Coomassie Brilliant Blue G-250 shifts from 
465 nm to 595 nm when the dye  binds to protein residues (Bradford 1976). A series of 
standard solutions is prepared from a set of protein solutions with known 
concentrations. The standard values obtained are then used to construct a standard curve 
to which the sample values measured are compared and the unknown concentrations are 
determined. As standards six bovine serum albumin (BSA) serial diluted solutions 
ranging from 0.1 to 1.3 mg/ml (1.25; 1; 0.63; 0.5; 0.31; 0.16) were used.  
5 µl of the standard solutions, the blank (0.2 M potassium phosphate buffer, pH 
7.4) and the samples were pipetted into a 96-well-plate. To each well 250 µl of Bradford 
Reagent was added and incubated 5 min at room temperature. The measurement was 
done at 595 nm with the Tecan spectrophotometer.  
 
 
 
51 
 
5.2.6 SDS polyacrylamide gel electrophoresis 
 
Sodium dodecyl sulphate (SDS) polyacrylamide gel electrophoresis (PAGE) is a 
technique used to separate proteins according to their size. The protein mobility in an 
electric field is a function of the polypeptide chain length or molecular weight. SDS, an 
anionic detergent, is used in SDS-PAGE to denature proteins to their primary linearised 
structure. To break disulphide bond linkages DTT is used. Hence, the protein retention 
time in the gel solely depends on the molecular mass and is not affected by the proteins„ 
native three-dimensional structures or intrinsic charges. The NuPAGE
®
 Bis-Tris 
Electrophoresis System was used. It is a neutral pH, discontinuous SDS-PAGE where 
the neutral pH environment ensures maximum stability of both proteins and gel matrix. 
Precast gels with a separating gel gradient of 4 – 12 % acrylamide concentration was 
used. Samples to be run on SDS-PAGE, containing about 2-5 µg of recombinant 
protein, were heated in the 1x NuPAGE
®
 LDS Sample Buffer at 95°C for 3 min before 
loading. The Page Ruler ™ Prestained Protein Marker was taken to estimate protein 
size. Both inner and outer electrophoresis chamber were filled with 1x NuPAGE
®
 SDS 
Running Buffer. When reducing conditions were required, 500 µl NuPAGE® 
Antioxidant were added into the inner chamber. The gel was run on constant voltage 
200 V for 35 min. 0.02 % Coomassie dissolved in 10 % acetic acid solution was used to 
stain protein bands. The gel was left in the staining solution from 6 hours to overnight 
with gentle agitation. After that, the gel was destained in 10 % acetic acid until the 
background was transparent.  
 
5.3 Preparation of GSNO according to Hart 
 
GSNO was prepared according to Hart 1985 by incubating equimolar quantities of 
glutathione and sodium nitrite in acidified water on ice (Hart 1985). First a 2 N HCl 
stock solution was prepared by mixing 16.5 ml 37 % HCl with 83.5 ml H2O. 2.5 ml of 
this solution was added to 5.5 ml H2O and in this solution 1.54 g (5 mmol) of 
glutathione was dissolved on ice until an ice-cold clear solution was achieved.  In the 
next step 0.345 g (5 mmol) of NaNO2 was added to this solution, which turned bright 
red immediately. After 40 min of stirring at 4°C in the cold room the solution was 
treated with 10 ml of ice-cold acetone and stirred for further 10 min. After the addition 
of acetone a pale-red precipitation appeared immediately. The precipitate was filtered 
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off and subsequently rinsed with 5 ml ice-cold water, 3 ml ice-cold acetone and dried 
overnight in the speedvac. The pink GSNO powder was stored frozen at -20°C. The 
GSNO purity was checked by measuring absorbance of a presumed 10 mM solution, 
prepared from 0.017 g of the GSNO dissolved in 5 ml of H2O, at 340 nm. GSNO stock 
solutions were freshly prepared before each experiment and their concentrations were 
determined spectrophotometrically by absorbance at 340 nm, using the extinction 
coefficient 840 M
-1
 cm
-1
. 
 
5.4 Kinetics 
 
Catalytic properties were determined by measuring the decrease in absorbance at 
340 nm. Both NADPH and GSNO  absorb at 340 nm and cause change in absorbance 
due to the enzymatic reaction which is influenced by both substrate consumption and 
coenzyme utilization (Jensen, Belka et al. 1998). The initial rates were calculated from 
the absorbance decrease using an additive extinction coefficient of GSNO and NADPH. 
The extinction coefficient measured at 340 nm is 6.220 M
-1
 cm
-1
 for NADPH and 840 
M
-1
 cm
-1
 for GSNO. Thus the additive extinction coefficient is 7.060 M
-1
 cm
-1
. The 
reaction velocity v was calculated in mol/mg . min, the amount of NADPH consumed in 
the reaction by 1 mg of enzyme per 1 min, using the equation below. The results were 
evaluated using Graph Pad Prism. 
 
 
 
Equation 1: The reaction velocity v in mol/mg . min, calculated as the amount of NADPH consumed in 
the reaction by 1 mg of enzyme per 1 min 
 
 v  reaction velocity in mol/mg . min 
 slope  change in absorbance per minute 
   additive extinction coefficient of NADPH and GSNO 
 Venzyme  volume of enzyme 
 Vreaction volume reaction volume 
 cenzyme  concentration of enzyme in mg/ml 
 
A reaction mixture of total volume 1 ml (see Table 13) consisted of varying 
concentrations of GSNO ranging from 25 µM to 600 µM (minimum of 10 different 
concentrations) as substrate, 0.1 mM NADPH (50 µl of 2 mM stock solution per 
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reaction), 1 mM DTPA (diethylene triamine pentaacetic acid, 100 µl of 10 mM stock 
solution per reaction), 0.1 M potassium phosphate buffer pH 7.4 (500 µl of 0.2 mM 
stock solution, see Table 12) and enzyme dissolved in potassium phosphate buffer pH 
7.4. GSNO and NADPH were prepared fresh before each assay and kept on ice. The 
exact concentration of the GSNO stock solution was determined spectrophotometrically 
before each series of measurements using the extinction coefficient of 840 M
-1
 cm
-1
. 
GSNO was protected from light by wrapping into aluminum foil. A concentration- and 
time-dependent stability test of GSNO was done. DTPA served as a metal chelator 
preventing GSNO decomposition in case of the presence of contaminating metal ions. 
Initial reaction velocities were measured at least three times for each substrate 
concentration. The reaction temperature was held constant at 25°C. Generally, the 
concentration of the enzyme must be much lower than the concentration of the 
substrate. In this thesis, a volume of enzyme solution, corresponding to 1 µg of protein 
(33 nM), was used per reaction. This volume was added to an appropriate volume of the 
reaction mixture resulting in 1 ml of total volume. A reference cuvette contained the 
reaction solution with potassium phosphate buffer pH 7.4 instead of the enzyme. 
 
Table 13: Reaction conditions kept during all kinetic measurements 
 
reaction conditions stock solution 
amount of stock solution 
used per reaction (µl) 
0.1 M potassium 
phosphate buffer 
0.2 M potassium phosphate 
buffer 
500 
1 mM DTPA 10 mM DTPA 100 
0.1 mM NADPH 
2 mM NADPH prepared fresh 
each time 
  50 
varying GSNO 
5 mM GSNO prepared fresh 
each time 
varying 
[E] << [S]  
corresponding to 1 µg of 
protein 
 H2O ad 1 ml 
 
To determine the kinetic constants, the GraphPad Prism equation for substrate 
inhibition was used to fit the values measured.  
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Equation 2: The reaction rate calculated using the GraphPad Prism equation for substrate inhibition 
 
y  reaction rate (mol/mg . min) 
x  the substrate concentration (µM) 
Vmax the maximum enzyme velocity (mol/mg . min) 
Km the Michaelis-Menten constant, corresponding to the substrate concentration of ½ Vmax  
(µM) 
Ki the dissociation constant for substrate binding where two substrates can bind to an 
enzyme (µM) 
 
From the values obtained from GraphPad Prism, the kcat constant, determining the 
number of molecules of the substrate converted by an enzyme per minute and the 
kcat/Km constant, determining the enzyme efficiency, were calculated.  
 
 
  
Equation 3: The kcat constant calculation 
Kcat defines the number of substrate molecule each enzyme site converts to product per minute. 
 
To calculate the molar enzyme concentration used in the equation for kcat determination 
the following equation was used.  
 
 
 
Equation 4: The molar enzyme concentration calculation based upon mass-volume percentage 
 
M indicates the molecular weight including the coding sequence plus additional tag, in 
Da, which corresponds to the unit g/mol. The molecular weights of all mutants were 
obtained from the amino acid sequences using “the ExPASy - Prot Param” internet tool. 
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Table 14: The molecular weights of all mutants expressed from the modified pET-28b(+)vector  
 
mutant  molecular weight of the CDS + tag (Da) 
CBR1wt 32.633 
CBR3wt 32.955 
K106Q 32.954 
SUMU 32.861 
97VA 32.923 
C143S 32.938 
SOE 32.879 
SOE P230W 32.969 
 
 
5.5 Concentrating CBR1 
 
For performing the Saville-Griess assay, a higher concentration of the protein 
solution was needed. The Amicon
®
 Ultra-4 centrifugal filter device was used to 
concentrate the samples. The device design incorporates the Millipore Ultracel
®
 low 
binding membrane, which enables sample recoveries from dilute solutions. These 
samples can be quickly ultrafiltered, allowing fast separation of solutes from low 
molecular weight compounds. Up to 4 ml sample was added into the Amicon Ultra filter 
unit and centrifuged at 7.500 x g until the solution was concentrated ca. 7 times. After 
that, the exact protein concentration was measured using the Bradford method as 
described before.  
 
5.6 Saville-Griess assay 
 
The Saville-Griess (SG) assay is a method to quantify S-nitrosothiols. The NO-
group is cleaved selectively from RS-NO by Hg
2+
 or Cu
2+
 ions. In the Saville reaction, 
first, due to the affinity of the metal ion to sulphur, a reversible complex between the 
S-nitrosothiol and the metal ion is formed. This coordination complex weakens the S-N 
bond which is now susceptible to the nucleophilic attack of water molecules. This attack 
then yields an equivalent of nitrous acid (Saville 1958). First, the nitrous acid is 
protonated  
HONO + H
+
 ↔ NO+ + H2O 
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and the originated reactive nitrosonium ion is used in the formation of an azo dye from 
sulphanilamide and N-1-naphthylethylenediamine (see Figure 9). The azo dye which 
has developed in this reaction is detected spectrophotometrically at 540 nm by means of 
a colour reaction (Griess 1879). In this work Cu
2+
 ions were used, which provide the 
same result as Hg
2+ 
ions,
 
but are less toxic. The sensitivity is extremely high, for as little 
as 2 x 10
-8
 g equivalents of a thiol in 1 ml of solution can be determined (Saville 1958). 
 
 
 
 
Figure 9: Formation of the azo dye in the Saville-Griess reaction 
 
A CBR1 solution at a concentration of at least 2 mg/ml was incubated in 2 mM 
GSNO for 2 hours at room temperature. The total reaction volume was up to 2.5 ml at 
most. As controls solutions without GSNO and CBR1, respectively, were used. After 
incubating all solutions including the controls were rebuffered via PD10 desalting 
columns. A mixture of 615 µl of 1.3 % sulphanilamide, 80 µl of  
N-(naphthyl)ethylenediamine, 80 µl of 25 mM CuCl2 and 25 µl of sample or standard 
solution (800 µl total volume) was pipetted into eppendorf tubes. For the blank H2O 
was used instead of CuCl2. The mixtures were incubated for 15 min at room 
temperature and the optical density at 540 nm was measured. The standard curve was 
constructed from 10 GSNO standard solutions of the concentrations 0, 10, 20, 40, 60, 
80, 100, 150, 200, 250 µM. All standard solutions were measured in duplicates. The 
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samples and both controls without GSNO or CBR1 were measured in triplicates. Two 
independent measurements were done.  
In addition to the Saville-Griess assay the enzymatic activity with 100 µM 
GSNO was determined with all samples (as described under “Kinetics”).  
 
5.7 Treatment with dithiothreitol (DTT) and ascorbic acid 
 
To assess the mechanism behind the apparent deactivation of CBR1 by incubation 
with GSNO (see results) 1.5 ml of the CBR1 and CBR3 solutions at a concentration of 
ca. 1mg/ml were treated with DTT and ascorbic acid. DTT is a strong reducing agent 
often used for reduction of disulphide bonds in proteins. Ascorbic acid has a capability 
to specifically reduce S-nitrosothiols releasing glutathione and oxidised products of NO 
(Kashiba-Iwatsuki, Yamaguchi et al. 1996).   
1.5 ml of the sample (c = ca. 1 mg/ml) was incubated with 30 mM (CBR1 and 
CBR3) or 100 mM  DTT (CBR3), and 10 mM ascorbic acid at room temperature for 2 
hours. For more details see Table 15. After incubation enzyme activity with 100 µM 
GSNO was determined.  
 
Table 15: Treatment of 1.5 ml protein, c = ca 1 mg/ml with DTT and ascorbic acid 
    
sample volume 1.5 ml 
and concentration ca. 
1 mg/ml 
reaction 
conditions 
 stock 
solution 
volume of 
the stock 
solution (ml) 
volume of 
water (ml) 
CBR1 incubated with 
GSNO in SG 
  10 mM 
ascorbic acid 
  50 mM 
ascorbic acid 
0.5 0.5 
CBR1 incubated with 
GSNO in SG 
  30 mM DTT 100 mM DTT 0.75 0.25 
CBR3 
  10 mM 
ascorbic acid 
  50 mM 
ascorbic acid 
0.5 0.5 
CBR3   30 mM DTT 100 mM DTT 0.75 0.25 
CBR3 100 mM DTT 500 mM DTT 0.5 0.5 
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5.8 GSNO concentration-dependent inactivation of CBR1 
 
To assess GSNO concentration dependency of the evident inactivation 125 µl of 
CBR1 at the concentration of about 1 mg/ml was incubated with different 
concentrations of GSNO ranging from 0 - 2 mM (0; 0.05; 0.1; 0.25; 0.5; 0.75; 1; 1.35; 
1.7; 2 mM) for two hours at room temperature. The total reaction volume was 250 µl. 
The incubated enzyme was rebuffered via PD 10 desalting columns and concentrated 
via Amicon
®
 Ultra-4 centrifugal filter device to the volume of ca. 0.5 ml. The protein 
concentration of all samples was measured using the Bradford method (described 
above) and the enzyme activity with 100 µM GSNO was determined.  
 
5.9 DTT concentration-dependent reactivation of GSNO-treated 
CBR1 
 
As inactivation of CBR1 had been confirmed in the previous assay, attempts were 
made to reactivate the enzyme by treatment with DTT. CBR1 was incubated with 2 mM 
GSNO for two hours at room temperature. To avoid spontaneous reactions between 
GSNO and DTT, the incubated enzyme was rebuffered and concentrated as mentioned 
above. After that, the inactivated enzyme was subjected to incubation with varying 
concentrations of DTT (0, 10, 20, 30, 50, 75, 100 mM in 250 µl total reaction volume) 
for 2 hours at room temperature, again followed by rebuffering and concentrating. The 
enzyme activity with 100 µM GSNO was determined before and after inactivation with 
GSNO as well as after treatment with DTT.  
 
5.10 His-tag cleavage using the TEV cleavage site of modified 
pET-28b(+) vector 
 
As mentioned in Methods, for cloning the slightly modified (by Yasser El-
Hawari) pET-28b(+) vector was used (see appendix). The modifications consist in the 
introduction of more restriction endonuclease sites and the incorporation of a TEV 
(tobacco etch virus) cleavage region (ENLYLQG in our sequence, ENLYFQG in 
sequences used in literature). This specific TEV cleavage site allows for cleavage of the 
6xHis-tag from the purified recombinant protein by the TEV protease enzyme. Together 
with thrombin, factor IX and enterokinase proteases, the TEV protease is the most 
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common enzyme used for His-tag removal which is essential in cases, when obtaining 
the protein in its natural condition without any additional tags e.g. for crystallisation or 
the cases when the His tag interferes with the enzyme activity is required. The 
advantage of the TEV protease is higher specificity in comparison to other proteases, 
which can digest the target protein in some cases (Kwon, Choi et al. 2005). Also a broad 
temperature range, including desired low temperatures (4-37°C) can be used for the 
TEV cleavage reaction (Polayes, Goldstein et al. 1994). However, the TEV cleavage 
efficiency is influenced both by the substrate and the tag and the ideal temperatures and 
enzyme concentration should be tested for every protein (Polayes, Goldstein et al. 
1994).  
The TEV cleavage conditions for CBR3 were investigated. The assay reaction 
mixture of total volume 110 µl consisted of 50 µl of CBR3 as a substrate (c = 1 µg/µl) 
in 100 mM Tris-Cl (pH 8), 1 mM DTT, and 5 µl of the TEV protease (c = 1 µg/µl) 
kindly provided by Prof. Dr. Axel J. Scheidig (Zoologisches Institut, Zentrum für 
Biochemie und Molekularbiologie Christian-Albrechts-Universität zu Kiel), together 
with the CFP-TEV-GFP protein which exhibits a TEV cleavage site. 2 µl of this CFP-
TEV-GFP protein (c = 10 µg/µl) were used as a substrate for the positive cleavage 
control. In addition to substrate the control reaction mixture of a total volume 20 µl 
contained 2 µl of TEV protease; other conditions were kept the same as explained 
above. As negative control, a reaction mixture of total volume 105 µl without TEV 
protease and containing 50 µl of CBR3 was prepared. The mixtures were incubated at 
room temperature (RT) for 6 hours. Additionally, the temperature of 4°C for CBR3 was 
used (see Table 16 for the composition of all reaction mixtures).   
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Table 16: Composition of reaction mixtures used for TEV cleavage  
The reactions were incubated for 6 hours; the conditions of all reactions were 100 mM Tris-Cl (pH 8) and 
1 mM DTT.  
c (CBR3) = 1 µg/µl, c (CFP-TEV-GFP) = 10 µg/µl, c (TEV protease) = 1 µg/µl 
 
substrate 
volume of 
substrate 
(µl) 
volume  
of TEV 
protease 
(µl) 
incubation 
temperature 
total 
reaction 
volume 
(µl) 
CBR3 50 5 RT 110 
CBR3 50 5 4°C 110 
CBR3 as a 
negative 
control 
50 0 RT 105 
CFP-TEV-
GFP as a 
positive 
control 
  2 2 RT   20 
  
 
5.11 Confirmation of the TEV cleavage  
 
To confirm the effective TEV cleavage the samples were purified via the 
QIAexpress Kit based on the Ni-NTA affinity principle. 20 µl of 50 % nickel slurry 
were added to the samples followed by incubation at 4°C for 30 min under gentle 
mixing. To pellet the resin the samples were centrifuged for 10 s at 15.000 x g at room 
temperature. The supernatants were transferred to a fresh tube. In the next step 35 µl of 
500 mM imidazol buffer (see Table 11) were added and incubated 15 min to elute the 
bound protein and then centrifuged for 10 s at 15.000 x g at room temperature. The 
elution and centrifugation step was repeated and both supernatants were collected in one 
tube.  
To analyze the successful TEV cleavage the supernatants from both steps were 
loaded on an SDS-PAGE gel as described in “SDS polyacrylamide gel electrophoresis“ 
chapter. The proteins with cleaved His-tag are not able to bind to nickel containing resin 
and should be found in the first collected fraction. 
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6 RESULTS AND DISCUSSION  
 
Despite 72 % identity at the amino acid level in the sequence alignment of 
CBR1 and CBR3 (see Figure 4), these two enzymes exhibit high differences in substrate 
specificity. In the present thesis we focused on GSNO as a substrate for CBR1 
(Bateman, Rauh et al. 2008). We tried to investigate the residues responsible for this 
property by changing some residues of CBR3 to correspond to CBR1. After that, we 
determined kinetic properties of the mutants and investigated the observed enzyme 
inhibition.  
 
6.1 Selection of the residues to be changed 
 
The GSH-binding site in CBR1 has been described by Bateman, Rauh et al. 2008. 
Bateman´s group had previously managed to crystallise CBR1 with its inhibitor OH-PP 
(hydroxy-1-tert-butyl-3-phenyl-1H-pyrazolo[3,4-d]pyrimidin-4-amine) and NADP 
(Tanaka, Bateman et al. 2005). For the structure determination of the CBR1*GSH 
complex they introduced GSH into the CBR1*OH-PP*NADP crystals using soaking 
experiments. The structure analysis confirmed the GSH bound in the CBR1 complex 
with OH-PP and NADP which allowed for characterisation of the GSH binding site 
(Bateman, Rauh et al. 2008).  
Inspired by the results of this structure analysis, some residues were selected for 
directed mutagenesis in CBR3 to correspond to CBR1. Bateman et al. described only 
one side chain interaction between GSH and CBR1, namely the interaction between the 
α-amine of GSH and glutamine at the position 106 in the sequence. Thus we decided to 
change this position in CBR3, a lysine, to glutamine. Furthermore, the residues 97Ser 
and 98Asp of CBR3 were mutated to 97Val and 98Ala found in CBR1. These residues 
were chosen because Bateman et al. had found out, that the glutamyl carboxylate of 
GSH is anchored to the 97Val NH group (Bateman, Rauh et al. 2008). The other 
mutant, called SUMU in this thesis, includes more residues changed. El-Hawari, Favia 
et al, (2009) have described a relatively big influence of the changed residues in this 
mutant for catalytic activity with isatin and 9,10-phenanthrenequinone as substrates (for 
the positions changed see Table 6). Also two other mutants, SOE and SOE P230W, 
were described by the mentioned authors (El-Hawari, Favia et al. 2009). All three 
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variants include the change in the sequence at the positions 236-244, which is one of the 
few regions revealing low sequence similarity in an alignment of CBR1 and CBR3 (see 
Figure 4). Moreover the Trp230 of CBR1, is, as mentioned in the theoretical part, one of 
the two amino acids coded by a triplet differing in all three bases and, moreover, is 
located close to the cofactor in the three-dimensional structure. Finally, the last residue 
changed in the CBR3 sequence was Cys143 changed to Ser. This change was done in 
order to break a putative disulphide bond between the Cys at the position 226 or 227 
and the Cys143. More details about this change will be discussed later. The changed 
positions of all mutants are shown in Figure 10. 
 
 
 
Figure 10: The crystal structure of CBR3 with the changed residues created in PyMOL 
The changed residues are shown in red, the NADP cofactor in yellow, in blue is displayed the         
surface of amino acids surrounding the cofactor at a distance of 5 Ångström (1 Ångström = 10-10m) 
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6.2 Cloning, overexpression and protein purification  
 
The insertion of the coding sequences for all CBR3 variants (wt, K106Q, 97VA 
and SUMU) into the pET-28b(+) vector was confirmed by loading the PCR samples 
from the reaction after ligation and transformation (see chapter 5.1.11) on the agarose 
gel. The primers used are mentioned in Table 9. The expected size 834 bp agreed well 
with the location on the gel for all samples. As a positive control the CBR3 coding 
sequence inserted into the pET-15b(+) vector was used for the PCR reaction.   
  
 
 
Figure 11: Confirmation of the incorporation of the fragments into the pET-28b(+) vector 
 
The samples framed in Figure 11 were selected for sequencing. However, the 
sequencing reaction failed in three of four samples sent, probably because of some 
residual ethanol from the purification to which the sequencing reaction is very sensitive. 
From then on rolling circle amplification (RCA) was performed to avoid this ethanol 
contamination. After that, the sequencing reactions were successful and all sequences 
were confirmed to be correct, using the web-based sequence analysis tools “Nucleic 
Acid Sequence Massager” and “ClustalW”. 
During Ni
2+
-affinity-based purification of the His-tagged CBR3 variants, the 
main protein peak fraction monitored at 280 nm during elution with imidazol was 
collected. An example of the protein elution is shown in Figure 12. First a minor peak, 
probably corresponding to some unspecifically bound fraction, appeared followed by 
the desired protein peak. Except for the 97VA variant, the protein peak looked the same 
in all variants and all the purifications. The 97VA variant peak was significantly lower, 
but the reason for this difference was not elucidated. 
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Figure 12: A representative chromatogram of Ni-NTA-based protein purification, here of the SOE 
mutant.  
The blue line indicates absorbance at 280 nm, the green line shows the increasing concentration of 
imidazol during elution. 
 
 
After rebuffering to 0.1 M potassium phosphate buffer pH 7.4, the concentration 
of the proteins was measured using the Bradford method (Bradford 1976). An example 
of the protein standard curve to which the samples were compared is shown in Figure 
13. 
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Figure 13: A typical BSA standard curve used for determination of protein concentration 
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The purity of the proteins was confirmed by SDS-polyacrylamide gel 
electrophoresis (SDS-PAGE) followed by Coomassie staining of the gel. To check and 
compare the purification process some samples were loaded both before and after 
purification (approximately 3 µg of pure protein were loaded). After purification all 
proteins showed pure single bands. Surprisingly, the location of the 97VA mutant band 
on the gel was higher than the other bands, indicating a higher molecular weight (Figure 
14). Also during purification, the fraction peak of this mutant was much lower in 
comparison to the other mutants, but the reason for these differences was not clarified. 
 
 
 
Figure 14: The confirmation of purity of the proteins on the SDS gel stained by Coomassie 
Samples on the left show not purified fraction after the ultracentrifugation step. 
 
6.3 GSNO stability proof 
 
First, GSNO, prepared according to Hart (Hart 1985), was checked for its purity 
by measurement of a presumed 10 mM solution at 340 nm. This solution was diluted 10 
times and the absorbance value of 0.832 was measured. This corresponds to a 
concentration of 9.9 mM of the undiluted solution and almost 100 % purity. Generally, 
S-NOs are very unstable substances and are decomposed very quickly. Although GSNO 
is more stable in comparison to other S-NOs (Singh, Wishnok et al. 1996), a time- and 
concentration-dependent stability test was done to eliminate any doubts of the substrate 
interactions in kinetics. As GSNO is a well water-soluble substance, high concentration 
solutions can be achieved. A set of solutions of GSNO concentrations ranging from 
50 – 1.500 µM (9 concentrations) was prepared and the absorbance at 340 nm was 
measured. A linear dependence was observed, confirming that GSNO is stable at high 
concentrations (Figure 15).  
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Figure 15: Concentration-dependent GSNO stability proof 
 
In the next step, a time-dependent stability test was performed. The UV 
spectrum from 200-800 nm of 5 mM GSNO solution was recorded for 2 hours. No 
changes in absorbance were observed within this time (results not shown).  
  
6.4 Kinetic properties of the constructs 
 
The catalytic properties of the successfully overexpressed and purified proteins 
were determined with GSNO as a substrate. Of all variants, only 3 mutants and CBR1wt 
showed activity, namely the already mentioned CBR1, SUMU, SOE and SOE P230W. 
The other mutants including CBR3wt, K106Q and 97VA were inactive towards GSNO. 
The data from two independent experiments, where initial velocities for each substrate 
concentration was measured in triplicates, are shown. All the resulting data are 
summarized in Table 17.  
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             CBR1 kinetic number 1  CBR1 kinetic number 2  
 
Vmax = 3.0 µmol/(mg.min) 
 
Vmax = 3.7 µmol/(mg.min) 
Km = 47 µM Km = 112 µM 
kcat = 97 min-1 kcat = 122 min-1 
kcat/Km = 2.1 (µM.min)-1 kcat/km = 1.1 (µM.min)-1 
Ki = 78 µM Ki = 69 µM 
 
Standard errors 
Vmax = 0.63 µmol/(mg.min) 
Km = 16.7 µM 
Ki = 23.57 µM 
 
Standard errors 
Vmax = 1.03 µmol/(mg.min) 
Km = 42.83 µM 
Ki = 24.09 µM 
 
 
         SUMU kinetic number1          SUMU kinetic number 2 
 
Vmax = 87.5 µmol/(mg.min) Vmax = 127 µmol/(mg.min) 
Km = 5167 µM Km = 8000 µM 
kcat = 2876 min
-1
 kcat = 4167 min
-1
 
kcat/km = 0.56 (µM.min)
-1
 kcat/km = 0.52 (µM.min)
-1
 
Ki = 3 µM Ki = 2.2 µM 
 
Standard errors 
Vmax = 1438 µmol/(mg.min) 
Km = 85831 µM 
Ki = 50.03 µM 
 
Standard errors 
Vmax = 2336 µmol/(mg.min) 
Km = 148531 µM 
Ki = 43.84 µM 
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 SOE kinetic number1            SOE kinetic number 2 
 
Vmax = 8.7 µmol/(mg.min) Vmax = 8.3 µmol/(mg.min) 
Km =  387µM Km = 360 µM 
kcat = 286 min
-1
 kcat = 273 min
-1
 
kcat/km = 0.74 (µM.min)
-1
 kcat/km = 0.75 (µM.min)
-1
 
Ki = 48.5 µM Ki = 46 µM 
 
Standard errors 
Vmax = 5.4 µmol/(mg.min) 
Km = 282.5 µM 
Ki = 34.1 µM 
 
Standard errors 
Vmax = 7.0 µmol/ µM (mg.min) 
Km = 355.2 µM 
Ki = 44.6 µM 
 
         SOE P230W kinetic number 1  SOE P230W kinetic number 2 
 
Vmax = 357 µmol/(mg.min) Vmax = 379 µmol/(mg.min) 
Km = 17887 µM Km = 16834 µM 
kcat = 11756 min
-1
 kcat = 12508 min
-1
 
kcat/km = 0.66 (µM.min)
-1
 kcat/km = 0.74 (µM.min)
-1
 
Ki = 0.68 µM Ki = 0.64 µM 
 
Standard errors 
Vmax = 16219 µmol/(mg.min) 
Km = 816036 µM 
Ki = 32.41 µM 
 
Standard errors 
Vmax = 15056 µmol/(mg.min) 
Km = 669911 µM 
Ki = 26.29 µM 
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Table 17: Comparison of kinetic parameters for the mutants with detected activity towards GSNO 
The model of substrate inhibition was used for data evaluation. R
2
 is a measure of the goodness of the fit. 
 
 Measurement number 1 Standard errors 
 
Km 
(µM) 
kcat 
(min-1) 
kcat/Km 
((µM.min)-1) 
Ki 
(µM) 
R2 Vmax 
(µmol/ 
(mg.min)) 
Km 
(µM) 
Ki 
(µM) 
CBR1 47 97      2.1 78 0.94         0.63         16.7 23.57 
SUMU 5167 2876      0.56   3 0.78   1438   85831 50.03 
SOE 387 286      0.74 48.5 0.90         5.4       282.5 34.1 
SOE P230W 17887 11756      0.66   0.68 0.87 16219 816036 32.41 
 
 Measurement number 2 Standard errors 
 
Km 
(µM) 
kcat 
(min-1) 
kcat/Km 
((µM.min)-1) 
Ki 
(µM) 
R2 Vmax 
(µmol/ 
(mg.min)) 
Km 
(µM) 
Ki 
(µM) 
CBR1     112     122      1.1 69 0.91         1.03         42.83 24.09 
SUMU   8000   4167      0.52   2.2 0.80   2336 148531 43.84 
SOE     360     273      0.75 46 0.82         7.0       355.2 44.6 
SOE P230W 16834 12508      0.74   0.64 0.90 15056 669911 26.29 
 
  
In all variants that showed activity, enzyme inhibition starting at a substrate 
concentration of about 100 µM was observed. The reason for this inhibition was 
investigated and will be explained later; first the kinetic parameters of the mutants will 
be discussed. To compare and determine the kinetic constants, non-linear regression 
analysis in GraphPad Prism was performed, using the model of substrate inhibition, 
explained in more detail in the Material and methods section. The calculated standard 
errors obtained with this model were very high in two cases (SUMU and SOE P230W). 
Either more precise data are needed to obtain a better fit or the model chosen for the 
calculation is incorrect. Also the R
2
 values, describing the quality of the fit, where a 
value of 1 signifies perfect agreement between the data and the regression curve, 
indicate that the model of substrate inhibition does not fit our data perfectly. Product 
inhibition may give a similar result, but this scenario is very unlikely as initial values 
were measured where the concentration of formed product is very low. However, R
2
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values from 0.8 to 0.95 may be sufficiently well to compare and discuss the kinetic 
parameters.  
 
6.4.1 CBR1 kinetics 
 
Bateman et al reported GSNO as an ideal CBR1 substrate. In our experiments, 
wild-type CBR1 showed the highest kcat/Km constant (2.1; 1.1 (µM.min)
-1
) and the 
lowest Km (47; 112 µM) from all the mutants, which means, that among all variants, 
CBR1 wt reduces GSNO with the highest efficiency. The comparison of our results and 
the kinetic constants reported by Bateman et al. reveals considerable differences. This 
can be explained by the fact that this group did not mention any substrate inhibition and 
thus used the unmodified Michaelis-Menten equation to calculate the kinetic constants. 
The highest GSNO concentration used in their work was 151 µM. Thus it is possible 
that only classical Michaelis-Menten kinetics was observed, as we observed the 
strongest inhibition at concentrations higher than that.  
 
6.4.2 Kinetics of the other mutants 
 
Of all prepared CBR3 variants activity was observed in three cases. The mutant 
called SOE showed the best activity as it reduced GSNO with a Km of about 400 µM 
and a kcat/Km-value of about 0.5 (µM.min)
-1
. The SOE mutant comprises the mutations 
at positions 236-244, which showed to be sufficient to activate the CBR3 enzyme for 
GSNO conversion, as CBR3 wt is inactive towards GSNO. Anyway, the enzyme 
efficiency never reaches the one of CBR1 wt, indicating that, for GSNO conversion, 
more residues are important. The addition of the mutation at the position 230 
(Pro230Trp) resulting in the SOE P230W mutant increased the Km and kcat values ca 45 
times, the ratio of kcat/Km and thus the enzyme efficiency was still comparable to the 
SOE mutant. The lowest, kcat/Km values were obtained with the SUMU mutant.  
Considering that the activity was found only in the constructs comprising the 
mutation at the positions 236-244, this area, or a part of it, appears to be important for 
the GSNO activity, although the individual residues responsible for the activity were not 
identified. The kcat/Km-values of the mutants and the CBR1 wild-type did not vary much 
and were still comparable. Neither exchanging lysine 106 of CBR3 to glutamine or the 
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mutations at the 97/98 positions discussed in chapter number 6.1 were sufficient to 
activate CBR3 towards GSNO. 
El-Hawari et al. investigated the kinetic properties of the SUMU, SOE and SOE 
P230W mutants towards isatin and 9,1-phenanthrenequinone as the substrates. This 
group reported the best enzyme efficiency for the SUMU mutant, followed by the SOE 
P230W and the SOE mutant (El-Hawari, Favia et al. 2009). The differences in the 
enzyme efficiency of the three mutants, demonstrated by the kcat/Km constant, were quite 
big as can be seen in the Table 18, the SUMU mutant showed even higher efficiency 
than the CBR1 wt. In comparison, the kcat/Km values obtained with the GSNO substrate 
were comparable for the three mutants and reached approximately 30-40 % of the 
CBR1 wt activity. 
 
Table 18: The kinetic constants for the SOE, SOE P230W and SUMU mutants reported by El-Hawari et 
al (2009) 
 
 Isatin 9,10-phenanthrenequinone 
 
Km 
(µM) 
kcat/Km 
((µM.min)-1) 
Km 
(µM) 
kcat/Km 
((µM.min)-1) 
CBR1 wt       7.8 13.5    35.4     8.9 
SOE 1600   0.24 > 78     0.54 
SOE P230W     47   5.3    56.4     5.7 
SUMU     22.5 18.9      4.3 107.9 
 
 
6.4.3 Investigation of the inactivity of CBR3 towards GSNO 
 
The obvious inactivation of CBR1 and all other active mutants at higher GSNO 
concentration led us to the idea that S-nitrosylation or S-glutathionylation of cysteines 
226 and/or 227 may be responsible for this inhibiting effect. This would agree with 
work by Tinguely and Wermuth (1999) in which they identified Cys227 as the only 
CBR1 cysteine residue involved in the glutathione binding process. The crystal 
structure of CBR3 (pdb-code 2HRB) suggests a disulphide bond between Cys227 and 
Cys143. We hypothesized that the presence or absence of this theoretical disulphide 
bond can play a role in the activity of the enzyme.  
To investigate the case where the disulphide bond would be needed for the 
activity we overexpressed the CBR3 enzyme in the E.coli Origami strain, which favours 
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the generation of disulphide bonds. But the overexpression in Origami cells did not 
influence the activity and the CBR3 enzyme was still inactive towards GSNO as a 
substrate. 
Considering the opposite theory, where the need of the breakage of the already 
created disulphide bond is necessary, we incubated CBR3 with 30 mM and 100 mM 
DTT. Furthermore, CBR3 was overexpressed and purified under reducing conditions 
with all the buffers used containing 1 mM DTT. None of these treatments, however, 
made CBR3 active towards GSNO.  
To investigate the possibility of inactivation of CBR3 by this putative disulphide 
bond by yet another approach, we mutated the cysteine at position 143 to serine. During 
the mutagenesis and cloning the PCR fragment size was checked on an agarose gel (see 
Figure 16) and after that the correct mutant sequence was confirmed. 
 
 
Figure 16: The Cys143Ser fragment size confirmation on the PCR gel 
 
The purified protein was loaded on an SDS-PAGE gel to check the purity (Figure 17).  
 
 
 
Figure 17: The C143S variant purified protein (Coomassie stain)  
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However, this CBR3 variant did not display activity towards GSNO either. 
Hence, presence or absence of the putative disulphide bond between the cysteines at the 
positions 226 or 227 and 143 is not responsible for the differences in activity between 
CBR1 and CBR3 towards GSNO as a substrate.  
To exclude the possible cysteine modification by S-nitrosylation which can be 
created in the cells during overexpression, purified CBR3 was incubated in 10 mM 
ascorbic acid, which would specifically reduce the S-N bonds. Also this experiment did 
not affect the enzyme‟s inactivity towards GSNO. 
 
6.5 The cause of the enzyme inhibition  
 
To investigate the reason for inactivation of CBR1 at higher GSNO 
concentrations we considered two possible modifications caused by GSNO, which 
could inactivate the enzyme. Both of them are common protein modifications and play 
key roles in metabolism and enzyme regulation in vivo. The first possible modification 
is S-nitrosylation, the second S-glutathionylation; both are described in the theoretical 
part.  
 
6.5.1 Assessment of the mechanism behind inactivation by GSNO  
 
The possible S-nitrosylation of the proteins was checked by performing the 
Saville-Griess assay (Griess 1879; Saville 1958). The standard curve constructed using 
GSNO solutions of known concentrations is shown in Figure 18. All measurements 
were done in duplicates.  
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Figure 18: Saville-Griess assay standard curve measured in duplicates 
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The absorbance values measured with CBR1 incubated with GSNO as a sample 
and the CBR1 wt as a control were similar. The measurement did not show any 
significant increase in absorbance of the sample measured at 540 nm in comparison to 
the controls, signifying no S-nitrosylation. The results from two independent 
measurements are shown in Table 19. 
 
Table 19: The results obtained by the Saville-Griess assay 
 
measurement 
number 
sample A540 A540 average  +  standard deviation 
1 
GSNO 
0.0249 
0.0272  ± 0.0050 0.0342 
0.0226 
CBR1 
0.0443 
0.0437 ± 0.0016 0.0416 
0.0453 
CBR1 + GSNO 
0.0225 
0.0429 ± 0.0161 0.0444 
0.0619 
2 
GSNO 
0.0343 
0.0293 ± 0.0036 0.0281 
0.0256 
CBR1 
0.0347 
0.0376 ± 0.0057 0.0456 
0.0325 
 0.0462 
0.0510 ± 0.0047 
CBR1 + GSNO 
0.0494 
0.0573 
 
 
Nevertheless, the activity measurement of the sample and the control from the 
Saville-Griess assay measured with 100 µM GSNO as substrate confirmed that CBR1 is 
really inactivated. The activity of the protein incubated with GSNO was ca 20-fold 
decreased in comparison to the CBR1 wt used as a control, see Table 20. 
 
Table 20: The inactivation of CBR1 caused by GSNO 
  
 
Enzyme activity 
∆A340/min*mg of 
protein 
CBR1 wt 0.830 
CBR1 incubated with GSNO 0.048 
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The first indication for S-glutathionylation as the reason behind the enzyme 
inhibition was that CBR1, which had been inactivated by treatment with GSNO, 
recovered activity after treatment with DTT (30 mM). The resulting activity was ca. 3 
times higher than in the case of the inactivated enzyme, although it did not reach the 
original CBR1 wt activity (see Table 21).  
Finally, also incubation of the GSNO-inactivated protein with ascorbic acid as a 
reducing agent was performed. As mentioned in “Material and methods”, the ascorbic 
acid has an ability to reduce specifically the S-N bonds of the S-nitrosothiols. This assay 
did not rescue the enzyme‟s activity, which was yet another indication that  
S-nitrosylation is not the cause of the inactivation.    
 
Table 21: The apparent reactivation of the inactivated CBR1 wt caused by the treatment with DTT 
 
 
Enzyme activity 
∆A340/min*mg of 
protein 
CBR1 wt 0.830 
inactivated CBR1 incubated with GSNO 0.048 
inactivated CBR1 treated with DTT 0.150 
inactivated CBR1 treated with ascorbic acid 0.059 
 
This strongly suggests disulphide bonds as the underlying cause of inactivation 
of CBR1. Next, to study this in more detail, the dose-dependency of inactivation by 
GSNO as well as of reactivation by DTT was investigated.  
 
6.5.2 In- and reactivation of CBR1 by GSNO and DTT 
 
To study the dose-dependency of CBR1 inactivation, the enzyme was treated 
with different GSNO concentrations for 2 h at room temperature, followed by 
assessment of enzyme activity. This resulted in the GSNO concentration-dependent 
inactivation shown in Figure 19. The y-axis defines the enzyme activity, expressed as 
change in absorbance at 340 nm (slope, ∆A) caused by one milligram of protein per 
minute. Figure 19 shows an obvious decrease in enzyme activity with increasing GSNO 
concentrations. The parallel CBR1 wt activity measurement showed activities around 
1.8 per milligram of protein per minute and excluded any interferences of the enzyme 
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stability within the incubation. The experiment was repeated and the results were 
confirmed (data not shown). 
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Figure 19: The GSNO concentration-dependent inactivation of CBR1  
CBR1 was incubated 2 h with different concentrations of GSNO, rebuffered and concentrated. Next, 
enzyme activity with 100 µM GSNO was measured. The loss of activity is clearly GSNO concentration-
dependent.  
 
Also the DTT concentration-dependency of reactivation was assessed. Here, 
CBR1 first inactivated with 2 mM GSNO was treated with different concentrations of 
DTT. DTT caused disulphide bond reduction and reactivated the enzyme, which is 
shown in Figure 20. Also this experiment was repeated and comparable values were 
measured in both assays (data not shown).  
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Figure 20: The DTT concentration dependent reactivation of CBR1 
The CBR1 inactivated by the incubation with 2 mM GSNO (2 hours) was reactivated with treating the 
inactivated CBR1 with different DTT concentrations for 2 hours. After rebuffering and concentrating the 
enzyme the activity was detected again with 100 µM GSNO.  
 
c (GSNO) [mM] 
∆A340/min*mg of protein  
 (2 measurements) 
0 1.60 2.06 
0.05 1.46 1.19 
0.1 1.40 1.16 
0.25 1.00 0.80 
0.5 0.74 0.86 
0.75 0.64 0.89 
1.35 0.70 0.61 
2 0.29 0.38 
c (DTT) [mM] 
∆A340/min*mg of protein  
 (2 measurements) 
0 0.35 0.27 
10 1.05 1.24 
20 2.27 0.71 
30 1.65 1.45 
50 2.18 1.68 
75 1.70 2.13 
100 1.64 2.00 
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The two latest experiments confirmed that the enzyme inactivation observed in 
the kinetic measurements is most likely caused by S-glutathionylation. However, to 
confirm the S-glutathionylation to 100 %, the modification should be verified by mass 
spectrometry. The GSNO concentration-dependent enzyme inactivation starts at low 
GSNO concentrations and the first part of the curve is very steep, which implies that the 
enzyme is sensitive to relatively low GSNO concentrations. As physiological GSNO 
concentrations can be as high as 1-10 µM (Gaston, Carver et al. 2003), this indicates a 
possible physiological role for S-glutathionylation of CBR1 triggered by GSNO.  
During reactivation of CBR1 by DTT, maximal CBR1 activity was achieved at a 
concentration of about 50 mM DTT and stayed stable at higher DTT concentrations up 
to 100 mM. This reactivation restored CBR1 activity to 100 % of its original activity.  
However, the role of this modification in vivo needs to be investigated in more detail. 
One possibility to test is, if S-glutathionylation and inactivation of CBR1 is equally 
caused by the oxidised form of glutathione, GSSG. This would suggest that CBR1 is 
inactivated during oxidative stress. 
 
6.5.3 The position determination of the S-glutathionylated cysteine 
 
The CBR1 amino acid sequence comprises 5 cysteines at positions 26, 122, 150, 
226 and 227. Tinguely and Wermuth (1999) mutated all these cysteines to alanines to 
investigate the involvement of the cysteines in the glutathione binding. Only the 
Cys227Ala mutant showed a role in glutathione binding. To assess if this cysteine, or 
Cys 226, are responsible for the inhibition that was revealed in the kinetics, Cys 226 and 
227 were changed to Ser by site-directed mutagenesis. The double digested SOE 
fragments with the desired mutations were cloned into the modified pET-28b(+) vector. 
However, the sequencing results showed that almost all of the first half of the sequence 
was missing. The solution of this problem was clarified; unfortunately the CBR1 
sequence displayed a restriction site for KpnI which was used for cloning. Therefore the 
first part of the sequence prior to the KpnI site was cut out (see Figure 21). The 
restriction sites for KpnI are displayed in yellow; the coding sequence is in bold. More 
details about the modified vector can be seen in the appendix.   
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Figure 21: The CBR1 sequence with the KpnI restriction site in the middle of the enzyme highlighted 
 
Despite the digestion of the CBR1 coding sequence, it could be seen, that the 
mutations are implemented correctly as the mutations are located in the second part of 
the enzyme. The modified pET-28b(+) provides a possibility of using another restriction 
enzyme, namely XmaI, instead of KpnI to clone the fragments into the pET-28b(+) 
vector. But because of lack of time this was not done and will be a task for the future 
continuators of the project.  
 
6.6 The His-tag cleavage 
 
The His-tag cleavage was done in order to achieve the protein without any 
additional tags, which is necessary e.g. for protein crystallisation, which is one of the 
future tasks of the project. Moreover, some cases are known where the C- or N- 
terminal His-tag influences the enzyme activity  (Ledent, Duez et al. 1997; Sayari, 
Mosbah et al. 2007). The temperatures chosen for the His-tag cleavage were room 
temperature and 4°C. The TEV protease used in this assay, has been shown to work at a 
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wide temperature range (4°C – 37°C) (Polayes, Goldstein et al. 1994). To assure the 
enzyme stability, we did not use 37°C but stuck to the above mentioned temperatures.  
The His-tag cleavage was confirmed by loading the samples and the control 
(explained in the chapters 5.10. and 5.11) on an SDS gel (Figure 22).  
 
  
 
Figure 22: The confirmation of the His-tag cleavage 
lane 1: TEV protease + CBR3 
lane 2: The unbound protein fraction incubated at room temperature (step 1 in chapter 5.10. and 5.11) 
lane 3: The unbound protein fraction incubated at 4°C (step 1 in chapter 5.10. and 5.11) 
lane 4: The unbound fraction of uncleaved CBR3 as control 
lane 5: The nickel-resin bound fraction incubated at room temperature (step 2 in chapter 5.10. and 5.11) 
lane 6: The nickel-resin bound fraction incubated at 4°C (step 2 in chapter 5.10. and 5.11) 
lane 7: The nickel-resin bound fraction of uncleaved CBR3 as control  
lane 8: The CFP-TEV-GFP positive control - not digested 
lane 9: The CFP-TEV-GFP positive control – digested 
 
 
The His-tag cleavage, shown in Figure 22, was proven by treating the samples 
with the nickel-containing slurry, which is able to bind only the His-tagged protein. 
Thus the cleaved protein is not able to bind to the resin and will be found in the first 
fraction (step 1), the protein which was not cleaved and still contains the His-tag will 
bind to the resin and will be found in the second fraction after imidazol elution (step 2). 
The cleavage was successful just in the case of incubation at room temperature (sample 
2, lane 2 and lane 5), where the band can be seen in the first unbound protein fraction, 
as well as in the eluted fraction, signifying that the cleavage was not 100 % and some 
uncleaved protein was bound to the resin. The digestion at 4°C did not work at all and 
the protein band could be found in the elution fraction, which is shown on the gel in 
sample 6. The sample 3 and 7 stands for the control CBR3 (without TEV cleavage) 
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correctly found in the fraction eluted by imidazol. Number 8 shows the control protein 
with the TEV cleavage region incorporated in the middle, which was cleaved by TEV 
protease at room temperature as shown in sample 9.  
 The result that only the room temperature cleavage worked showed that the 
cleavage conditions need to be investigated more thoroughly, especially the 
temperature, the TEV protease amount and the incubation time. All these factors 
together with the protein structure influence the cleavage efficiency and are specific for 
each protein. 
 
6.7 The physiological relevance of the results obtained 
 
6.7.1 S-glutathionylation and its protective role in oxidative stress 
 
Many authors have described the S-glutathionylation as a response to oxidative 
stress and a link between oxidative stress and protein alteration (Cotgreave and Gerdes 
1998). To protect  the cell against reactive oxygen species the reversibility of the 
S-glutathionylation is important and was described in a number of cell types (Schuppe-
Koistinen, Gerdes et al. 1994; Seres, Ravichandran et al. 1996). This modification may 
protect proteins from irreversible oxidation leading to damaged malfunctioning proteins 
associated with many diseases (Casadei, Persichini et al. 2008). Examples of proteins 
affected by S-glutathionylation during oxidative stress are creatine kinase, actin, 
glycogen phosphorylase b, glyceraldehyde-3-phosphate dehydrogenase (GADPH) or 
HIV-protease.  
 
6.7.2 Other enzymes inhibited by GSNO-mediated S-glutathionylation 
in relation to CBR1  
 
Protein inhibition caused by GSNO-mediated S-glutathionylation is described for 
some enzymes, e.g. the inhibition of glyceraldehyde-3-phosphate dehydrogenase, an 
NAD
+
-dependent enzyme involved in glycolysis and gluconeogenesis is specifically 
caused by GSNO (Mohr, Hallak et al. 1999). The levels of the S-glutathionylated 
GADPH protein are increased during exposure to oxidative stress and GADPH was 
identified as the major S-glutathionylated protein in endothelial cells during the 
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hydrogen peroxide exposition. After removal of the oxidant the enzyme activity was 
recovered (Schuppe-Koistinen, Moldeus et al. 1994).  
Another enzyme inhibited by GSNO-mediated S-glutathionylation is aldose 
reductase (AKR1B1), converting short- and medium-chain aldehydes to their 
corresponding alcohols. It is an NADPH-dependent stress related protein and 
participates in glucose metabolism and osmoregulation. The S-glutathionylated inactive 
form of the enzyme is formed by the GSNO from exogenously delivered NO and GSH. 
In contrast, endogenously generated NO causes S-nitrosylation which activates the 
enzyme. Thus the NO donor can either increase or decrease the enzyme activity (Baba, 
Wetzelberger et al. 2009).  
 Thioredoxin (Trx), an enzyme with a wide range of functions e.g. in apoptosis, 
as antioxidant or regulator of transcription factors also can undergo  
S-glutathionylation resulting in the inactivation of the protein, especially under 
conditions of oxidative stress (Casagrande, Bonetto et al. 2002). Interestingly, Trx has 
the ability to break the S-N bond in the GSNO molecule, thus Trx is inhibited by its 
own substrate as in the case of CBR1. Trx can furthermore autoactivate itself by 
deglutathionylation (Casagrande, Bonetto et al. 2002). For CBR1 this ability was not 
investigated.  
 The physiological relevance of the discovery that CBR1 is inhibited by GSNO at 
higher concentration needs to be investigated. The major question is, does the  
S-glutathionylation observed in vitro take place in vivo? Physiological GSNO levels are 
1-10 µM (Gaston, Carver et al. 2003); here, however, the effect of concentrations below 
50 µM was not assessed. Nevertheless, when GSNO concentration-dependent 
inactivation of CBR1 was assessed, inhibition was evident from the lowest GSNO 
concentration which suggests that in vivo S-glutathionylation of CBR1 is possible. Here 
another question arises. Would the oxidised form of GSH, GSSG, be able to  
S-glutathionylate CBR1? And if yes, will the modification be reversible or not? This 
will be the tasks for the future project continuators to investigate.  
The physiological significance of CBR1 S-glutathionylation may lie in the 
protection of the enzyme from irreversible damage during oxidative stress by the 
formation of a reversible mixed-disulphide as mentioned above and CBR1 would be 
inactivated by oxidative stress. During oxidative stress, the level of NO, which is 
needed for GSNO formation, is increased. Another question worth addressing might be 
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whether the redox state of the cell determined by the ratio of [GSH]/[GSSG] may 
influence enzyme activation/inactivation via GSNO formation from GSH and NO.  
 
6.8 The role of CBR1 in GSNO metabolism and the redox state of the 
cell 
 
The fact, that CBR1 metabolises GSNO was unknown until 2008, when Bateman 
et al detected the ability of CBR1 to metabolise GSNO. Before discovering this, only 
ADH3, already mentioned in the theoretical part, was known to regulate endogenous 
levels of GSNO by reduction using NADH as a cofactor and thus regulating the 
dynamic equilibrium between GSNO and S-nitrosylated proteins (Jensen, Belka et al. 
1998; Liu, Hausladen et al. 2001; Staab, Hellgren et al. 2008). Cofactor requirement 
often reflects the role of enzymes in the normal redox state of the cell. In contrast to 
NADPH-dependent CBR1, ADH3 requires NADH as the cofactor. The redox state of 
the cell is determined by the ratio of these two cofactors and its reduced/oxidised forms. 
In the cell environment the NADPH/NADP
+
 ratio is about 100 while the NADH/NAD
+
 
form is about 1/700, which shows the different functions of these two cofactors (Ido 
2007; Ying 2008). Hence, as ADH3 requires NADH for GSNO reduction, which is 
scarce in the cell, CBR1 might play a more important role in physiological GSNO 
reduction as it uses the much more available cofactor NADPH. 
 
6.9 Possible effects of the S-glutathionylation of CBR1 on the 
quinone-reducing activity 
 
CBR1 is able to metabolise a wide spectrum of endogenous and exogenous 
substrates, namely prostaglandins, steroids, lipid aldehydes, aromatic aldehydes and 
ketones, quinones and NNK. The quinone reducing activity enables to reduce quinone-
containing substances and thus to excrete them. The docking experiments done by  
El-Hawari et al showed the H-bond interaction of the quinone substrate and the tyrosine 
194 of the enzyme. This H-bond was situated between the Trp230 and Met 142 in the 
catalytic cleft. Moreover this author group highlighted the importance of the Trp 230 
(El-Hawari, Favia et al. 2009).  
To investigate if S-glutathionylation of CBR1 would affect CBR1-mediated 
quinone reduction, it can be speculated that, considering that Cys 227 (or Cys 226) is 
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the most promising candidate for S-glutathionylation, the enzyme activity may not be 
affected as, until now, there are no references of those cysteines and its role in  
CBR1-mediated quinone reduction. But first of all the Cys residue, responsible for the 
enzyme inactivation, must be determined.  
 
6.10 Summary of the results 
 
In the present thesis some residues of CBR3 were changed to correspond to CBR1 
by site-directed mutagenesis. After the successful cloning of the fragments, comprising 
the desired changes in the sequence, the catalytic properties of the wild type of both 
CBR1 and CBR3 enzymes together with the mutants were investigated. It was found 
out that wild-type CBR3 was inactive in vitro towards GSNO as a substrate. The CBR3 
mutants comprising changes at the positions 236-244 (SUMU, SOE and SOE P230W) 
were able to metabolise GSNO although the activity did not achieve the CBR1 wild 
type´s values. The Km of the mutants varied widely, but the kcat/Km values of the mutants 
were comparable and about 3 times lower than those of the CBR1 wild type.  
Next it was discovered, that at GSNO concentrations higher than 100 µM CBR1 
together with the CBR3 mutants were inhibited. Further experiments put forward  
S-glutathionylation as the most probable inactivating modification. First S-nitrosylation 
was excluded performing the Saville-Griess assay and after that S-glutathionylation was 
indicated by the DTT-caused reactivation of the enzyme. The inactivation was shown to 
be GSNO concentration-dependent as well as the reactivation by DTT, which resulted 
in an activity increase up to 100 % of activity of the untreated enzyme.  
The next aim of the thesis was to detect the cysteine responsible for the inactivation 
of CBR1. Unfortunately these experiments were not finished and will be the task for the 
future project continuators. 
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7 APPENDIX 
 
7.1 The pET-28b(+) modified vector 
 
The pET-28b(+) vector modified by Yasser El-Hawari containing TEV cleavage site 
and HisTag 
 
BglII PstI KpnI XmaI BamHI other restriction sites XhoI 
bold underlined: start and stop codon 
bold dotted: HisTag 
bold: TEV cleavage site (Literature: ENLYFQG, our: ENLYLQG) 
underlined: coding sequence 
 
AGATCTCGATCCCGCGAAATTAATACGACTCACTATAGGGGAATTGTGAGC
GGATAACAATTCCCCTCTAGAAATAATTTTGTTTAACTTTAAGAAGGAGATA
TACCATGGGCAGCAGCCATCATCATCATCATCACGAGAACCTGTATCTGCA
GGGTACCCCCGGGATG ... coding sequence ... TGAGGATCCGAATTCGAGCTCC 
GTCGACAAGCTTGCGGCCGCACTCGAGCACCACCACCACCACCACTGA 
 
 
7.2 The sequences of the mutants 
 
CBR1 (in the pET-28b(+) vector) 
 
ATGGGCAGCAGCCATCATCATCATCATCACGAGAACCTGTATCTGCAGGGTACCCCCGGG 
ATGTCGTCCGGCATCCATGTAGCGCTGGTGACTGGAGGCAACAAGGGCATCGGCTTGGCCAT
CGTGCGCGACCTGTGCCGGCTGTTCTCGGGGGACGTGGTGCTCACGGCGCGGGACGTGACGC
GGGGCCAGGCGGCCGTACAGCAGCTGCAGGCGGAGGGCCTGAGCCCGCGCTTCCACCAGCT
GGACATCGACGATCTGCAGAGCATCCGCGCCCTGCGCGACTTCCTGCGCAAGGAGTACGGG
GGCCTGGACGTGCTGGTCAACAACGCGGGCATCGCCTTCAAGGTTGCTGATCCCACACCCTT
TCATATTCAAGCTGAAGTGACGATGAAAACAAATTTCTTTGGTACCCGAGATGTGTGCACAG
AATTACTCCCTCTAATAAAACCCCAAGGGAGAGTGGTGAACGTATCTAGCATCATGAGCGTC
AGAGCCCTTAAAAGCTGCAGCCCAGAGCTGCAGCAGAAGTTCCGCAGTGAGACCATCACTG
AGGAGGAGCTGGTGGGGCTCATGAACAAGTTTGTGGAGGATACAAAGAAGGGAGTGCACCA
GAAGGAGGGCTGGCCCAGCAGCGCATACGGGGTGACGAAGATTGGCGTCACCGTTCTGTCC
AGGATCCACGCCAGGAAACTGAGTGAGCAGAGGAAAGGGGACAAGATCCTCCTGAATGCCT
GCTGCCCAGGGTGGGTGAGAACTGACATGGCGGGACCCAAGGCCACCAAGAGCCCAGAAG
AAGGTGCAGAGACCCCTGTGTACTTGGCCCTTTTGCCCCCAGATGCTGAGGGTCCCCATGGA
CAATTTGTTTCAGAGAAGAGAGTTGAACAGTGGTGA 
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CBR3 (in the pET-28b(+) vector) 
 
ATGGGCAGCAGCCATCATCATCATCATCACGAGAACCTGTATCTGCAGGGTACC 
ATGTCGTCCTGCAGCCGCGTGGCGCTGGTGACCGGGGCCAACAGGGGCATCGGCTTGGCCAT
CGCGCGCGAACTGTGCCGACAGTTCTCTGGGGATGTGGTGCTCACCGCGCGGGACGTGGCGC
GGGGCCAGGCGGCCGTGCAGCAGCTGCAGGCGGAGGGCCTGAGCCCGCGCTTCCACCAACT
GGACATCGACGACTTGCAGAGCATCCGCGCCCTGCGCGACTTCCTGCGCAAGGAGTACGGG
GGGCTCAATGTACTGGTCAACAACGCGGCCGTCGCCTTCAAGAGTGATGATCCAATGCCCTT
TGACATTAAAGCTGAGATGACACTGAAGACAAATTTTTTTGCCACTAGAAACATGTGCAACG
AGTTACTGCCGATAATGAAACCTCATGGGAGAGTGGTGAATATCAGTAGTTTGCAGTGTTTA
AGGGCTTTTGAAAACTGCAGTGAAGATCTGCAGGAAAGGTTCCACAGTGAGACACTCACAG
AAGGAGACCTGGTGGATCTCATGAAAAAGTTTGTGGAGGACACAAAAAATGAGGTGCATGA
GAGGGAAGGCTGGCCCAACTCACCTTATGGGGTGTCCAAGTTGGGGGTCACAGTCTTATCGA
GGATCCTGGCCAGGCGTCTGGATGAGAAGAGGAAAGCTGACAGGATTCTGGTGAATGCGTG
CTGCCCAGGACCAGTGAAGACAGACATGGATGGGAAAGACAGCATCAGGACTGTGGAGGA
GGGGGCTGAGACCCCTGTCTACTTGGCCCTCTTGCCTCCAGATGCCACTGAGCCACAAGGCC
AGTTGGTCCATGACAAAGTTGTGCAAAACTGGTAA 
 
 
K106Q (in the pET-28b(+) vector) 
 
ATGGGCAGCAGCCATCATCATCATCATCACGAGAACCTGTATCTGCAGGGTACC 
ATGTCGTCCTGCAGCCGCGTGGCGCTGGTGACCGGGGCCAACAGGGGCATCGGCTTGGCCAT
CGCGCGCGAACTGTGCCGACAGTTCTCTGGGGATGTGGTGCTCACCGCGCGGGACGTGGCGC
GGGGCCAGGCGGCCGTGCAGCAGCTGCAGGCGGAGGGCCTGAGCCCGCGCTTCCACCAACT
GGACATCGACGACTTGCAGAGCATCCGCGCCCTGCGCGACTTCCTGCGCAAGGAGTACGGG
GGGCTCAATGTACTGGTCAACAACGCGGCCGTCGCCTTCAAGAGTGATGATCCAATGCCCTT
TGACATTCAGGCTGAGATGACACTGAAGACAAATTTTTTTGCCACTAGAAACATGTGCAACG
AGTTACTGCCGATAATGAAACCTCATGGGAGAGTGGTGAATATCAGTAGTTTGCAGTGTTTA
AGGGCTTTTGAAAACTGCAGTGAAGATCTGCAGGAAAGGTTCCACAGTGAGACACTCACAG
AAGGAGACCTGGTGGATCTCATGAAAAAGTTTGTGGAGGACACAAAAAATGAGGTGCATGA
GAGGGAAGGCTGGCCCAACTCACCTTATGGGGTGTCCAAGTTGGGGGTCACAGTCTTATCGA
GGATCCTGGCCAGGCGTCTGGATGAGAAGAGGAAAGCTGACAGGATTCTGGTGAATGCGTG
CTGCCCAGGACCAGTGAAGACAGACATGGATGGGAAAGACAGCATCAGGACTGTGGAGGA
GGGGGCTGAGACCCCTGTCTACTTGGCCCTCTTGCCTCCAGATGCCACTGAGCCACAAGGCC
AGTTGGTCCATGACAAAGTTGTGCAAAACTGGTAA 
 
 
SUMU (in the pET-28b(+) vector) 
 
ATGGGCAGCAGCCATCATCATCATCATCACGAGAACCTGTATCTGCAGGGTACC 
ATGTCGTCCTGCAGCCGCGTGGCGCTGGTGACCGGGGCCAACAGGGGCATCGGCTTGGCCAT
CGCGCGCGAACTGTGCCGACAGTTCTCTGGGGATGTGGTGCTCACCGCGCGGGACGTGGCGC
GGGGCCAGGCGGCCGTGCAGCAGCTGCAGGCGGAGGGCCTGAGCCCGCGCTTCCACCAACT
GGACATCGACGACTTGCAGAGCATCCGCGCCCTGCGCGACTTCCTGCGCAAGGAGTACGGG
GGGCTCAATGTACTGGTCAACAACGCGGCCGTCGCCTTCAAGAGTGATGATCCAATGCCCTT
TGACATTAAAGCTGAGATGACACTGAAGACAAATTTTTTTGCCACTAGAAACATGTGCAACG
AGTTACTGCCGATAATGAAACCTCATGGGAGAGTGGTGAATATCAGTAGTTTGATGAGCTTA
AGGGCGTTTGAAAACTGCAGTGAAGATCTGCAGGAAAGGTTCCACAGTGAGACACTCACAG
AAGGAGACCTGGTGGATCTCATGAAAAAGTTTGTGGAGGACACAAAAAATGAGGTGCATGA
GAGGGAAGGCTGGCCCAACTCACCTTATGGGGTGTCCAAGTTGGGGGTCACAGTCTTATCGA
GGATCCTGGCCAGGCGTCTGGATGAGAAGAGGAAAGCTGACAGGATTCTGGTGAATGCGTG
CTGCCCAGGATGGGTGAAGACAGACATGGCGGGACCCAAGGCCACCAAGAGCCCAGAGGA
GGGGGCTGAGACCCCTGTCTACTTGGCCCTCTTGCCTCCAGATGCCACTGAGCCACAAGGCC
AGTTGAACAGTGACAAAGTTGTGCAAAACTGGTAA 
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97VA (in the pET-28b(+) vector) 
 
ATGGGCAGCAGCCATCATCATCATCATCACGAGAACCTGTATCTGCAGGGTACC 
ATGTCGTCCTGCAGCCGCGTGGCGCTGGTGACCGGGGCCAACAGGGGCATCGGCTTGGCCAT
CGCGCGCGAACTGTGCCGACAGTTCTCTGGGGATGTGGTGCTCACCGCGCGGGACGTGGCGC
GGGGCCAGGCGGCCGTGCAGCAGCTGCAGGCGGAGGGCCTGAGCCCGCGCTTCCACCAACT
GGACATCGACGACTTGCAGAGCATCCGCGCCCTGCGCGACTTCCTGCGCAAGGAGTACGGG
GGGCTCAATGTACTGGTCAACAACGCGGCCGTCGCCTTCAAGGTTGCTGATCCAATGCCCTT
TGACATTAAAGCTGAGATGACACTGAAGACAAATTTTTTTGCCACTAGAAACATGTGCAACG
AGTTACTGCCGATAATGAAACCTCATGGGAGAGTGGTGAATATCAGTAGTTTGCAGTGTTTA
AGGGCTTTTGAAAACTGCAGTGAAGATCTGCAGGAAAGGTTCCACAGTGAGACACTCACAG
AAGGAGACCTGGTGGATCTCATGAAAAAGTTTGTGGAGGACACAAAAAATGAGGTGCATGA
GAGGGAAGGCTGGCCCAACTCACCTTATGGGGTGTCCAAGTTGGGGGTCACAGTCTTATCGA
GGATCCTGGCCAGGCGTCTGGATGAGAAGAGGAAAGCTGACAGGATTCTGGTGAATGCGTG
CTGCCCAGGACCAGTGAAGACAGACATGGATGGGAAAGACAGCATCAGGACTGTGGAGGA
GGGGGCTGAGACCCCTGTCTACTTGGCCCTCTTGCCTCCAGATGCCACTGAGCCACAAGGCC
AGTTGGTCCATGACAAAGTTGTGCAAAACTGGTAA 
 
 
C143S (in the pET-28b(+) vector) 
 
ATGGGCAGCAGCCATCATCATCATCATCACGAGAACCTGTATCTGCAGGGTACC 
ATGTCGTCCTGCAGCCGCGTGGCGCTGGTGACCGGGGCCAACAGGGGCATCGGCTTGGCCAT
CGCGCGCGAACTGTGCCGACAGTTCTCTGGGGATGTGGTGCTCACCGCGCGGGACGTGGCGC
GGGGCCAGGCGGCCGTGCAGCAGCTGCAGGCGGAGGGCCTGAGCCCGCGCTTCCACCAACT
GGACATCGACGACTTGCAGAGCATCCGCGCCCTGCGCGACTTCCTGCGCAAGGAGTACGGG
GGGCTCAATGTACTGGTCAACAACGCGGCCGTCGCCTTCAAGAGTGATGATCCAATGCCCTT
TGACATTAAAGCTGAGATGACACTGAAGACAAATTTTTTTGCCACTAGAAACATGTGCAACG
AGTTACTGCCGATAATGAAACCTCATGGGAGAGTGGTGAATATCAGTAGTTTGCAGTCTTTA
AGGGCTTTTGAAAACTGCAGTGAAGATCTGCAGGAAAGGTTCCACAGTGAGACACTCACAG
AAGGAGACCTGGTGGATCTCATGAAAAAGTTTGTGGAGGACACAAAAAATGAGGTGCATGA
GAGGGAAGGCTGGCCCAACTCACCTTATGGGGTGTCCAAGTTGGGGGTCACAGTCTTATCGA
GGATCCTGGCCAGGCGTCTGGATGAGAAGAGGAAAGCTGACAGGATTCTGGTGAATGCGTG
CTGCCCAGGACCAGTGAAGACAGACATGGATGGGAAAGACAGCATCAGGACTGTGGAGGA
GGGGGCTGAGACCCCTGTCTACTTGGCCCTCTTGCCTCCAGATGCCACTGAGCCACAAGGCC
AGTTGGTCCATGACAAAGTTGTGCAAAACTGGTAA 
 
 
SOE (in the pET-15b(+) vector) 
 
ATGGGCAGCAGCCATCATCATCATCATCACAGCAGCGGCCTGGTGCCGCGCGGCAGCCAT 
ATGTCGTCCTGCAGCCGCGTGGCGCTGGTGACCGGGGCCAACAGGGGCATCGGCTTGGCCAT
CGCGCGCGAACTGTGCCGACAGTTCTCTGGGGATGTGGTGCTCACCGCGCGGGACGTGGCGC
GGGGCCAGGCGGCCGTGCAGCAGCTGCAGGCGGAGGGCCTGAGCCCGCGCTTCCACCAACT
GGACATCGACGACTTGCAGAGCATCCGCGCCCTGCGCGACTTCCTGCGCAAGGAGTACGGG
GGGCTCAATGTACTGGTCAACAACGCGGCCGTCGCCTTCAAGAGTGATGATCCAATGCCCTT
TGACATTAAAGCTGAGATGACACTGAAGACAAATTTTTTTGCCACTAGAAACATGTGCAACG
AGTTACTGCCGATAATGAAACCTCATGGGAGAGTGGTGAATATCAGTAGTTTGCAGTGTTTA
AGGGCGTTTGAAAACTGCAGTGAAGATCTGCAGGAAAGGTTCCACAGTGAGACACTCACAG
AAGGAGACCTGGTGGATCTCATGAAAAAGTTTGTGGAGGACACAAAAAATGAGGTGCATGA
GAGGGAAGGCTGGCCCAACTCACCTTATGGGGTGTCCAAGTTGGGGGTCACAGTCTTATCGA
GGATCCTGGCCAGGCGTCTGGATGAGAAGAGGAAAGCTGACAGGATTCTGGTGAATGCGTG
CTGCCCAGGACCAGTGAAGACAGACATGGCGGGACCCAAGGCCACCAAGAGCCCAGAGGA
GGGGGCTGAGACCCCTGTCTACTTGGCCCTCTTGCCTCCAGATGCCACTGAGCCACAAGGCC
AGTTGGTCCATGACAAAGTTGTGCAAAACTGGTAA 
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SOEP230W (in the pET-15b(+) vector) 
 
ATGGGCAGCAGCCATCATCATCATCATCACAGCAGCGGCCTGGTGCCGCGCGGCAGCCAT 
ATGTCGTCCTGCAGCCGCGTGGCGCTGGTGACCGGGGCCAACAGGGGCATCGGCTTGGCCAT
CGCGCGCGAACTGTGCCGACAGTTCTCTGGGGATGTGGTGCTCACCGCGCGGGACGTGGCGC
GGGGCCAGGCGGCCGTGCAGCAGCTGCAGGCGGAGGGCCTGAGCCCGCGCTTCCACCAACT
GGACATCGACGACTTGCAGAGCATCCGCGCCCTGCGCGACTTCCTGCGCAAGGAGTACGGG
GGGCTCAACGTACTGGTCAACAACGCGGCCGTCGCCTTCAAGAGTGATGATCCAATGCCCTT
TGACATTAAAGCTGAGATGACACTGAAGACAAATTTTTTTGCCACTAGAAACATGTGCAACG
AGTTACTGCCGATAATGAAACCTCATGGGAGAGTGGTGAATATCAGTAGTTTGCAGTGTTTA
AGGGCTTTTGAAAACTGCAGTGAAGATCTGCAGGAAAGGTTCCACAGTGAGACACTCACAG
AAGGAGACCTGGTGGATCTCATGAAAAAGTTTGTGGAGGACACAAAAAATGAGGTGCATGA
GAGGGAAGGCTGGCCCAACTCACCTTATGGGGTGTCCAAGTTGGGGGTCACGGTCTTATCGA
GGATCCTGGCCAGGCGTCTGGATGAGAAGAGGAAAGCTGACAGGATTCTGGTGAATGCGTG
CTGCCCAGGATGGGTGAAGACAGACATGGCGGGACCCAAGGCCACCAAGAGCCCAGAGGA
GGGGGCTGAGACCCCTGTCTACTTGGCCCTCTTGCCTCCAGATGCCACTGAGCCACAAGGCC
AGTTGGTCCATGACAAAGTTGTGCAAAACTGGTAA 
 
 
7.3 The 100 bp DNA ladder 
 
 
 
7.4 The protein molecular weight marker  
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cGMP cyclic guanosine monophosphate 
CR carbonyl reducing enzyme 
DNA  deoxyribonucleic acid 
dNTPs  deoxynucleotide triphosphates 
DTPA diethylenetriaminepentaacetic acid  
DTT  dithiothreitol 
E. coli  Escherichia coli 
EDTA  ethylenediaminetetraacetic acid 
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ER endoplasmic reticulum 
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hCBR1,3 human CBR1, CBR3 
HCl  hydrochloric acid 
iNOS inducible NOS 
IPTG  isopropyl-D-1-thiogalactopyranoside 
kDa  kilodalton 
LB meduim Luria-Bertani Medium 
Mr relative molecular mass 
NaCl  sodium chloride 
NAD
+
/NADH  nicotinamide adenine dinucleotide 
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NADP
+
/NADPH nicotinamide adenine dinucleotide phosphate 
(oxidised/reduced) 
NEB New England Biolabs 
Ni-NTA nickel-nitrilotriacetic acid 
NKK 4-(methylnitrosamino)- 1-(3-pyridyl)-1-
butanone  
nNOS neuronal NOS 
NO nitric oxide 
NOS nitric oxide synthase 
NOS1, 2, 3 nitric oxide synthase1, 2, 3 
NOx oxides of nitrogen 
O2 oxygen 
ODx  optical density at x nm 
PCR polymerase chain reaction 
PDI protein didsulfide isomerase 
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PGE2 prostaglandin E2 
PGF2α prostaglandin F2 α 
QR quinone reductase 
RCA  rolling circle amplification 
RCC reactive carbonyl compound 
rpm  revolutions per minute 
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SDR  short-chain dehydrogenase/reductase 
SDS  sodium dodecyl sulfate 
SDS-PAGE  SDS polyacrylamide gel electrophoresis 
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SOD superoxide dismutase 
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Tris  tris(hydroxymethyl)aminomethane 
Trx thioredoxin 
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UV/VIS utraviolet/visible spectroscopy 
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wt wild type 
 
Amino acid letter code 
 
 
  
Amino acid Three letter code One letter code 
Alanine Ala A 
Arginine Arg R 
Asparagine  Asn N 
Aspartic acid Asp D 
Cysteine Cys C 
Glutamine Gln Q 
Glutamic acid Glu E 
Glycine Gly G 
Histidine His H 
Isoleucine Ile I 
Leucine Leu L 
Lysine Lys K 
Methionine Met M 
Phenylalanine Phe F 
Proline Pro P 
Serine Ser S 
Threonine Thr T 
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Valine Val V 
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